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1.1 Neurodegenerative disorders and Alzheimer 
The word “neurodegeneration” etymologically is composed of the prefix “neuro-“, 
which designates the neurons, and “degeneration”, which refers, in the biological 
field, to a process of losing structure or functions. Therefore, neurodegeneration 
corresponds to any pathological condition primarily affecting neurons. In practice, 
neurodegenerative diseases represent a set of pathologies of the central nervous 
system, characterized by a chronic and progressive process of neuronal death. The 
neurons deterioration is the main cause of the generation of irreversible damage, 
with consequent alteration of brain functions that lead to cognitive and motor deficits, 
or behavioural disorders. They arise for unknown reasons and progress in a 
relentless manner1. Among these, the most common are Alzheimer's disease (AD), 
Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS).  
As regard AD or PD, the main risk factor for developing a neurodegenerative 
disorder is the increasing age. Over the past century, the growth rate of the 
population aged 65 has far exceeded that of the whole population. Therefore,  the 
proportion of elderly citizens is destined to increase and, with this, the proportion of 
persons suffering of a neurodegenerative disorder1.  
Particularly, recent studies have estimated more than 35 million people living with 
dementia worldwide, the majority of whom are thought to have Alzheimer’s disease 
(50-75%)2. In 2040, the increase in the number of cases could reach 81.1 million of 
people3. A recent report by the National Center for Health Statistics (NCHS), USA,  
points out that the number of deaths due to heart attack, stroke, AIDS or cancer has 
decreased significantly, while there is an increase in cases of death due to AD4. 
Therefore, it is clear that AD represents a major public health concern and it must 
be identified as one of the priorities in research. Even if there are already approved 
treatments to alleviate the symptoms, there is the need to better understand these 





The AD was first described in 1907 by the German psychiatrist and neuropathologist 
Alois Alzheimer, who analysed, by autopsy, the brain tissue of a 55 years woman 
patient, died for dementia and revealed extracellular plaques and intraneural 
neurofibrillary tangles, currently considered the hallmarks of the disease5. The AD is 
characterized pre-mortem by a progressive loss of memory,  speech and recognition 
of people and post-mortem by neuritic plaques containing amyloid β peptide and 
neurofibrillary tangles, where the phospho-tau protein is accumulated6. 
 
Figure 1: Image of a whole brain and in section, of a healthy person (left) and affected by AD 
(right). 
1.2 Causes of the Alzheimer development 
The causes of the disease are not yet clear, but it is possible to identify different 
factors that increase the probability of disease onset. The early-onset AD is 
correlated to genetic factors, being genes mutations responsible for only 6%–8% of 
all Alzheimer disease cases6. An example is given by individuals with Down 
syndrome, a disorder characterized by the presence of three couples per cell of 
chromosome 21, which causes mental retardation and a characteristic physical 
appearance. These individuals develop AD by the age of forty. This occurs because 
the gene encoding APP (amyloid protein precursor), responsible for the production 
of the β-amyloid protein (Aβ), is located on chromosome 21. Therefore individuals 




way7. Since, the percentage of presenile dementia due to genetic factors is very low, 
the environmental factors should have an important role in the development of 
disease pathology. Recent studies highlighted that lower educational and 
occupational attainment, female sex, low mental ability in early life and reduced 
physical activity during late life could increase the risk for the disease. As well as 
epidemiological factors like head trauma, heart disease, diabetes, smoking or 
obesity could influence the AD development6. However, the main cause of the 
disease is certainly age. In fact, the probability to develop the disease increases 
considerably exceeded the threshold of 65 years. 
From a biological point of view, the AD is characterized by three distinct 
neuropathological abnormalities:  
1) intracellular neurofibrillary tangles; 
2) extracellular plaques; 
3) high level of oxidative stress. 
These factors are responsible of the damage to the biological target and the neuronal 
death. 
1.2.1 Intracellular neurofibrillary tangles 
Neurofibrillary tangles (NFTs) are intracellular aggregates of the 
hyperphosphorylated Tau protein. Tau is a microtubule-associated protein, that 
stabilized microtubules and is expressed in the axon.  
To better understand the role of neurofibrillary tangles in AD, it is important to take 
into account the morphology of neuronal cells. The neuron is characterized by a 
central zone, called pyrenophore, which contains the nucleus and the organelles and 
a peripheral one, consisting of the cytoplasmic extensions, the dendrites and the 
axon. The latter ends with the synaptic buttons, which have the task of receiving and 






Figure 2: Neuron structure. 
The axon inner part is characterized by microtubules which, in normal healthy 
neurons, are stabilized by Tau protein. In AD, Tau is hyperphosphorylated and 
disassociated from microtubules, becoming insoluble and forming NFTs. Indeed, 
phosphorylated Tau is unable to bind microtubules and forms insoluble polymeric 
aggregates, which assemble in paired helical filaments (Figure 3)8. This process 
induces the cell death.  
 
Figure 3: Illustration of  Tau protein function, in the case of healthy person (left) and in the case of 
AD (right): while in the first case the protein holds the microtubules together, in the latter they break 
down leading to axon atrophy.  
1.2.2 Formation of extracellular plaques 
Extracellular plaques are formed by fibrils of a protein constituted by 40-42 residues, 
named β-amyloid peptide (Aβ). It is a fragment of a membrane protein molecule, 
constituted by 695-770 residues and defined amyloid precursor protein (APP), which 
has various physiological functions. It comprises three parts, the extracellular N-




terminal domain. In the amyloidogenic process, Aβ is released by APP during a step-
by-step process, catalysed by two proteolytic enzymes, β- and γ-secretase7. In the 
case of non-amyloidogenic pathway, a third secretase, α-secretase, cleaves Aβ 
sequence, preventing its production4 (Figure 4). 
 
Figure 4: A) Non-amyloidogenic process, involving α-secretase followed by γ-secretase is show; B) 
Amyloidogenic process, involving β- and γ-secretase. 
 
β-amyloid peptides have a pronounced tendency to aggregate in aqueous solution. 
In AD brain the major forms identified are Aβ (1-40) and Aβ (1-42). The first form is 
soluble in biological fluids (~90%), while Aβ (1-42) is less abundant in biological 
fluids but is the predominant species found in plaque deposits, due to its highest 
propensity for aggregation and fibrillogenesis9.To explain the occurrence of amyloid 
deposits, two hypotheses were proposed: amyloid cascade hypothesis and metal 
ion deposit. 
According to amyloid cascade hypothesis, the neurodegeneration begins with 
aggregation of monomeric Aβ. The misfolding of the APP protein and the following 




aggregated into oligomer, through hydrophobic interactions and hydrogen bonds, 
then they form protofibrils, that finally generate insoluble plaques10 (Figure 6). 
According to this hypothesis, the oligomers can act as nucleation centres in the brain 
for the formation of new oligomers, generating higher-ordered aggregates4. 
The formation of the fibrils involves a structural change of the Aβ, which passes from 
a random coil state to β-sheet. Spectroscopic analysis of amyloid-based fibrils 
indicates that these are arranged perpendicular to the axis of the fibril, in a parallel 
or antiparallel way, in a structure known as "cross beta structure"7 (Figure 5). 
 
 
Figure 5: Cross beta structure. 
The metal ions are important in many cellular processes. They allow the function of 
different metalloproteins (Cytochrome C-oxidase, Cu/Zn superoxide dismutase) and 
in the brain they take part in the neuronal activity within the synapses (Zn2+ and Cu2+ 
especially). Therefore, cells have developed a sophisticated machinery for 
controlling metal-ion homeostasis. A breakdown of these mechanisms could alter 
the ionic balance, causing several neurodegenerative disorders, like AD9. In fact, 
people who are affected of AD present higher concentration of metal ions than 
healthy individuals (metal ion deposit). Hence, in the aggregation process, also the 
role of the metal ion should be taken into account. Studies highlight that copper (II) 
can be bound by Aβ, enhancing the aggregations, the stabilization of the oligomeric 





Figure 6: Mechanism for the amyloid plaques formation: amyloid cascade hypothesis (right) and 
metal ion deposit (left)4. 
In vitro experiments show that the precipitation of Aβ peptides is rapidly induced by 
Zn (II) and Cu (II) ions under physiological conditions (pH = 7.4). Besides, Cu(II) 
binding to soluble Aβ accelerates the aggregation, especially under mild acid 
conditions, similar to that found in AD brains11. Fe (III) ions exhibits a similar 
behaviour, too10. 
These metals, besides participating in the aggregation of Aβ peptides, can also 
facilitate the generation of reactive oxygen species (ROS) including hydrogen 
peroxide (H2O2), which may form hydroxyl radicals through the Fenton reaction. 
Hence, the Aβ toxicity is also attributable to the production of oxidizing species, 
responsible for cellular and tissue oxidative stress. 
1.2.3 ROS and oxidative stress 
One of the main causes of cellular damage and degenerative diseases is given by 
free radicals. A predominant cellular free radical is the superoxide anion: together 
with hydrogen peroxide and hydroxyl radicals, it is defined as Reactive Oxygen 
Species (ROS)12. ROS give rise to fast short-range and non-selective oxidation 
steps, being responsible for the “oxidative stress”13. The oxidative stress is a 
process, characterized by unbalance between the production and the elimination of 
oxidizing chemical species. Recent studies point out that the human brain produces 
more than 1011 free radicals per day, hence, the breakdown of the equilibrium in pro-
oxidant vs antioxidant homeostasis result in oxidative stress, generating free radicals 
that could damage the biological target, like DNA, proteins and nucleic acids14 






Figure 7: Process of production/elimination of ROS 
Superoxide anion is called primary ROS, since it is directly produced from 
mitochondria during the first reduction within the respiratory chain (1): 
O2 + e-→ O2•- (1) 
At a cellular level, the antioxidant activity is carried out by the combined action of 
specific enzymes: superoxide dismutase (SOD), catalase (CAT) and glutathione 
peroxidase (GHS). The SOD induce the superoxide anion dismutation to molecular 
oxygen and hydrogen peroxide, according to the reaction (2): 
O2•- → O2 + e- 
O2•- +2H+ + e-→ H2O2 
2O2•- +2H+              H2O2 + O2 (2) 
Subsequently, CAT and GHS use hydrogen peroxide as primary substrate to 
catalyse its conversion in water through the reaction 3, and activation through 








H2O2 → O2 + 2H+ + 2e- 
H2O2 + 2H+ + 2e- → 2H2O2 
2H2O2              H2O +O2 (3) 
H2O2            2H2O  (4) 
These reactions point out that CAT enzymes during the dismutation of hydrogen 
peroxide produce oxygen and water, while the role of GSH is to deactivate oxidizing 
compound. During this process GHS is converted  to its oxidizing form, GSSG, which 
subsequently is reduced to GHS, through GHS reductase, inducing the 
transformation of NAPH into NADP+ (Figure 8). 
 
Figure 8: Oxidation/reduction cycle of glutathione  
Other ROS are generated by Fenton reaction (reaction 6), that involves the metallic 
ions, previously reduced by superoxide radical anion, and H2O2, to produce hydroxyl 
radical OH•14: 
Fe3+/Cu2+ + O2•- → Fe2+/Cu+ + O2 (5) 
Fe2+/Cu+ + H2O2 → Fe3+/Cu2+ + OH• + OH- (6) 
O2•- + H2O2 → O2 + OH• + OH- (7) 
The reaction 7 is the Haber Weiss cycle and promote the formation of hydroxyl 




1.2.4 The correlation between oxidative stress and β-amyloid peptides 
Transition metal ions, particularly Fe(III) and Cu (II) could form complexes with the 
β-amyloid peptides. Recent studies highlight that the copper ions, accumulated in 
amyloid plaques forms Cu–Aβ complexes, which catalyses the production of ROS 
(Figure 9). 
 
Figure 9: The pathogenesis of AD showing the involvement of metal ions 
Aβ peptides have the ability to reduce Cu2+ to Cu+ and Fe3+ to Fe2+ (8) and these 
reduced metal ions can react with O2 to produce superoxide anions (9) that easily 
generates hydrogen peroxide (10). The generated H2O2 species may react with 
another reduced metal species forming OH● radicals via the Fenton (6) and Haber 
Weiss (7) reactions10. 
Aβ + Fe3+/Cu2+ → Aβ + Fe2+/Cu+ (8) 
Fe2+/Cu+ + O2 → Fe3+/Cu2+ + O2•- (9) 
2O2•- +2H+ → H2O2 + O2 (10) 
The reduction of metal ions is accompanied by oxidation of Aβ, in particular of the 




the transmembrane domain. The methionine residue is oxidized to the 
corresponding sulfoxide. The Aβ aggregates penetrate the membrane cell, through 
the transmembrane domain, assuming an α-helix structure, which has 3.6 residues 
per turn. This is the key to foster the oxidation of methionine residue, since Met35 is 
close to Ile31. The oxygen of Ile31 is more electronegative than sulphur and it pulls 
the electron density toward it, facilitating the one-electron oxidation of Met-35 to form 
sulfuranyl free radical MetS•+. Subsequently, the sulfaranyl radical causes the 
peroxidation of membrane lipids15 (Figure 10). 
 
Figure 10: Peroxidation mechanism of membrane lipids by amyloid peptides 
1.3 Therapeutic solutions and new perspective  
In the last decades, the research focused on understanding the pathogenesis of AD 
failed in the development of drugs for the etiological treatment, i.e. drugs that act on 
the causes of the disease. Among the five approved drugs by the "US Food and 
Drug Administration", four are inhibitors of acetylcholinesterase (AChEIs) and only 
one is a non-cholinergic drug, the N-methyl-d-aspartate receptor (NMDAr) 
antagonist. In fact, another peculiarity observed in AD consists in the loss of the 
neurotransmitters functionality, such as acetylcholine due to the hydrolysis caused 
by the enzyme Acetylcholinesterase (AChE)16. Other approaches focus on different 





• metal chelators; 
• modulators of the aggregation of Aβ peptides; 
• antioxidants. 
Nevertheless, the AD is a complex pathology and the therapies developed in the last 
20 years can only alleviate the symptoms of disease, temporary slowing down the 
loss of memory and of cognitive functions, without modifying or blocking neuronal 
degeneration. Furthermore, they are efficient for a limited period of time and when 
the disease is still at an early stage. The lack of effective therapies lies in the 
numerous aspects that make AD so critical. This led the research in recent years to 
focus on the development of multi-target drugs, with features that can promote 
multiple approaches, simultaneously. 
 
1.3.1 Metals chelators  
The brain requires high metal ion concentrations to carry out its numerous essential 
function, within the synapses (Zn2+) and for the metalloproteins functioning (Cu/Zn-
SOD). However, the metal ion homeostasis is severely dysregulate in AD, indeed, 
people affected by this neurodegenerative disease presented abnormal levels of 
Cu(II), Zn(II) and Fe(III)9.  
The intracellular concentration of free copper, that does not cause oxidative damage 
is 10-18 M14. The extracellular copper concentration in normal brain is about 0.2-
1.7μM, while in the amyloid plaques the copper concentration could reach 400μM. 
In contrasts, intracellular Cu level are lower in AD brain9. 
An interesting approach is the one based on the design of drugs, capable of 
sequestrating the excess of metal ion. These molecules compete with the peptides 
for the metal ions, reducing the neurotoxicity initiated by the Aβ-complexes and 
refurbishing metal ion homeostasis in the brain. These drugs are known as MPAC, 
Metal Protein Attenuating Compounds and must have particular features: a 
moderate chelating ability, to compete with the formation of the metal complex with 
Aβ, without disturbing the metal homeostasis. Moreover they must be characterized 
by a low toxicity and low molecular weights (<500 Da). Finally, they must be 




simultaneously have sufficient hydrophobicity to cross the Blood Brain Barrier (BBB), 
an anatomical brain component with the function of selecting the passage of only 
agents useful for metabolic functions 4,10,17.  
The clioquinol (CQ, 5-chloro-7-iodo-8-hydroxyquinoline) is the prototypic MPAC, 
since its small hydrophobicity, moderate affinity for metal ions and its capacity to 
cross the Blood Brain Barrier (BBB)17. In addition, it also has the ability to chelate 
copper (II) and zinc (II) with the ratio of 2 : 1, CQ : metal10 (Figure 11), whose binding 
constants are log K1 (Cu) = 12.5, log K2 (Cu) = 10.9, log K1 (Zn) = 8.5 and log K2 
(Zn)= 7.69. However, due to the possible neurotoxicity and mutagenic impurities the 
development of CQ as anti-Alzheimer's drug was suspended. 
 
Figure 11:  A) CQ and B) complex CQ : metal 2:1 structures. 
Prana Biotechnology, in collaboration with Barnham and coworkers, synthesized a 
second generation MPAC PBT2, that has higher solubility and increased BBB 
permeability as compared with CQ9. 
PBT2 is a 8-OH quinoline derivative of CQ without iodine atom (Figure 12), that has 
been demonstrated to be able to prevent the production of Aβ oligomers and to 
dissolve the existing Aβ oligomers. In people with mild Alzheimer's dementia, PTB2 
appears to be safe and well tolerated. Unfortunately, recent studies showed that 
there is no significant decrease of the Aβ levels in mild AD patients. 
 




To increase the chances of success, currently, the chelators are also designed to 
integrate the chelating function with other features, in order to block also other 
molecular events involved in the disease. For example, Deferiprone(DFP, 3- 
hydroxy-1,2-dimethylpyridin-4(1H)-one) is a chelator used for the treatment of 
thalassaemia. Its shows strong affinity for iron, copper and zinc. Although its scaffold 
presents too low hydrophobicity to cross BBB, its low molecular weight (MW = 139) 
and suitable structure make DFP amenable to an optimization . Another example is 
given by the curcumin, whose enolic form possess a good chelating ability to bind 
copper (II). Cu(II)–curcumin complex can also scavenge free-radical. Moreover, 
studying led on transgenic mouse demonstrated few side effect end toxicity issues 
(Figure 13)10. 
 
Figure 13: A) structure of DFP and B) Cheto-enolic equilibrium of curcumin  
1.3.2 Modulator for Aβ peptides aggregation  
Neurodegenerative disorders are characterized, in part, by the misfolding and 
subsequent aggregation of different peptides and proteins into various structures18.  
In particular, in the AD the APP cleavage causes the formation of amyloid fibrils, one 
of the main factor of the neurons death. Hence, targeting Aβ aggregation is 
considered an effective therapeutic strategy4. The strategies that allow the inhibition 
of protein aggregation and amyloid fibril formation involve: 





• limitation of the amyloid monomer proliferation, through the inhibition of 
secretase enzymes; 
• redirection of the amyloid fibril formation into non cytotoxic pathway. In fact, 
the fibril toxicity is correlated to the formation of transmembrane ion channels, 
due to the permeation of the amyloid oligomers in the cell membrane; the 
interaction between the latter and the oligomers activates a sequence of 
negative events for the cell19,18. 
In the recent years, modulators of Aβ aggregation are developed, depending upon 
their chemical structure they are defined as peptide-based modulators and small 
molecule-based modulators. Peptide-based inhibitors are based on sequence from 
5 to 15 of natural or unnatural amino acids. The key point in the design of the 
molecules is related to the hydrophobic core (KLVFF) of Aβ peptides. The KLVFF 
sequence plays a central role in the initiation of Aβ aggregation and in the fibrils 
elongation.  Hence, the challenge is to find  hydrophobic peptides that competes with 
the hydrophobic core of the Aβ peptide. KLVFF and LPFFD have been reported to 
be effective in the inhibition of Ab fibrillogenesis both in vitro and in vivo20,21. Even if 
peptide-based drugs are very specific and effective, their poor bioavailability limit 
their use as potential therapeutic agents. 
The modulation of Aβ aggregation using small molecules can also exploit  
hydrophobic interactions. Natural phenol, like curcumin, resveratrol, and 
epigallocatechin-3-gallate (EGCG) have been shown to be effective in decreasing 
the development of Aβ plaques in the brain, through their antioxidant and 
aggregation inhibition properties22 (Figure 14). HEWL study (Hen egg white 
lysozyme) a protein known to stack in an analogue way, demonstrated that the 
presence of almost three OH groups on various phenolic group are essential for 
efficient inhibition of the aggregation by polyphenols18.  
Since these drugs have a limited efficacy, the attention is moving towards others 
solutions. Indeed, the institutions such as the Alzheimer's Drug Discovery 
Foundation and the European Research Council are discouraging the search in the 






Figure 14: Structure of A) Curcumin, B) resveratrol and C)ECGC 
 
1.3.3 Molecules with antioxidant biomimetic activity 
As described previously, one of the main cause of AD is ROS overproduction.  At 
the cellular level, the ROS detoxification occurs via the combined action of 
antioxidant enzymes: superoxide dismutase (SOD), catalase (CAT) and glutathione 
peroxidase (GHS). Therefore, recent studies are focused on the design of molecule 
able to mimic the activity of these natural enzymes. In order to keep the level of 
superoxide radicals under control, mammals possess two classes of SODs. Mn-
SODs are located in the mitochondrial matrix, as tetramers, and in the cytoplasm of 
bacteria, as dimers. The active centre is characterized by a distorted trigonal 
bipyramidal geometry, where the single Mn is coordinated  by two histidines and one 
aspartic acid residue in the equatorial plane, while one histidine and one solvent 
molecule occupy the axial position. Cu/Zn-SOD is present in the cytosol and contains 





Figure 15: Active sites of Cu/Zn-SOD (left) and Mn-SOD (right) 
The copper (II) is a distorted square pyramidal geometry. The coordination in the 
reduced state differs from the one in the oxidized state. In the first case, Cu(II) is 
coordinated by three histidine nitrogen atoms (His44, His118, His46), while in the 
oxidized state there is a water molecule and the His61, which is a bridge between 
the two metal centres23. Zn (II) is in a distorted tetrahedral geometry, bound to the 
nitrogen atoms of His78, His65, His61 and by the oxygen of the Asp81 residue 
(Figure 16). 
 




The superoxide radical anion binds selectively to the sterically hindered active site24, 
through a funnelling effect, that electrostatically guides the radical anion through a 
channel formed  by positively charged amino acid residues25.  
During the SOD turnover, the redox active copper centre cycles between Cu(II) and 
Cu (I) oxidation states upon interaction with O2•- (reaction 11 and 12), while Zinc 
appears to play a role in the overall enzyme stability and in facilitating a broader pH 
independence, in the rage 7-7.826,27,28.  
O2•- + CuIIZnII-SOD → O2 + CuIZnII-SOD (11) 
O2•- +2H+ + CuIZnII-SOD →  H2O2 + CuIIZnII-SOD (12) 
Through an inner sphere electron transfer mechanism, there is simultaneously the 
oxidation of the superoxide radical anion and the reduction of the metal centre, with 
the release of molecular oxygen. At the structural level, the concomitant breaking of 
the copper–imidazolate bond  is fostered by protonation of the imidazolate, which is 
assisted by the solvent. After, a second O2•- is reduced and associated with two 
protons, producing hydrogen peroxide and re-oxidizing copper. In this second step, 
the His induces the exit of hydrogen peroxide, protonating the superoxide radical 
anion coordinated on Cu (I), which is oxidized again to Cu (II)25 (Figure 17).   
 
Figure 17: Mechanism of O2•- dismutation, catalysed by Cu/Zn-SOD25 
The two steps occur with a rate constant of  kcat ≈ 2 · 109 M-1s-1, the rate is close to 





SOD enzymes are not enough to detoxify the cell. First, the dismutation of 
superoxide radical anion, mediated by the SOD, yields H2O2, which is a strongly 
oxidizing species, able to diffuse within the cell compartments, causing several 
damages. Moreover, in the condition of oxidative stress, the Cu/Zn-SOD could react 
with H2O2, generating radical species, according to the Fenton-like reaction:  
H2O2 + CuIIZnII-SOD → H+ + HO2• + CuIZnII-SOD (13) 
H2O2 + CuIZnII-SOD → OH• + OH- + CuIIZnII-SOD (14) 
Studies have demonstrated that the hydroxyl radical generate in the active site can 
break the bond between the copper and the histidine, causing copper loss with 
deactivation of the enzyme24. 
As regard the hydrogen peroxide, its concentration is regulated by two enzymes: the 
catalase (CAT) and glutathione peroxidase (GSH). The latter induces the activation 
of H2O2, oxidizing the NAPH or others substrates. While CAT role is to convert H2O2 
in water and molecular oxygen with high efficiency. 
 
Figure 18: Structure of Fe-CAT and Fe coordination in the active site29. 
Two families of natural catalase are known. The most common catalase is the one 
based on iron-heme cofactor. These catalases are characterized by tetramers of 




protoporphyrin  plane, the Fe (II) is bound to different His and to one Asn, while 
below there are Tyr and Arg residues29 (Figure 18). 
The dismutation of hydrogen peroxide, through Fe-CAT precedes with a two steps 
mechanism. First, the oxidation of prosthetic group causes the concomitant oxidation 
of Fe(III) to Fe(IV), generating a radical cation on the porphyrin (15). After, a second 
H2O2 reacts with radical cation, regenerating the enzyme and producing water and 
molecular oxygen (16). 
FeIIIPor + H2O2 → (FeIV = O)Por+• + H2O (15) 
(FeIV = O)Por+• + H2O2 → FeIIIPor + H2O + O2 (16) 
The second class of catalase enzyme are the MnCAT. The active site of binuclear 
manganese enzyme contains two Mn ions, triply bridged, by μ1,3-carboxylate from a 
Glu residue (Glu66) and by two water molecule (W1 and W2). Glu35 is coordinated 
to Mn1 and simultaneously establishes a hydrogen bond with the W2 water 
molecule. While Glu148 acts as bidentate ligand, coordinating the Mn2 with the two 
carboxylate oxygens. The last coordination site for Mn1 and Mn2 is occupied by 
His69 and His181, respectively. The arrangement of the ligands produces 
octahedral coordination at both metal centres30 (Figure 19).  
 
Figure 19: Binding site of  L. Plantarum MnCAT30. 
As regard the mechanism, during the catalytic cycle, each two metal centres perform 
a one-electron redox cycle, through two half reactions: 
H2O2 + {Mn2 (III,III)} → O2 + {Mn2 (II,II) + 2H+} (17) 




In the oxidative half-reaction (17) hydrogen peroxide is oxidized to dioxygen, and the 
manganese cluster is reduced. While, in the reductive half-reaction (18) the reduced 
metallocluster delivers the electrons and protons to a second molecule of H2O2 to 
form two water molecules31. 
 
Figure 20: Hydrogen peroxide dismutation mechanism31. 
In the molecular mechanism, based on structural data, the neutral hydrogen 
peroxide substrate reaches the active site and coordinates to Mn1, displacing the 
water molecule in the apical position (Figure 20,2). At this point an electron transfer 
from hydrogen peroxide to the mental centres occurs, while the Glu178 plays a role 
in facilitating movement of protons from the bound substrate to the bridging solvents. 
This proton-coupled electron transfer generate the dioxygen product of the reaction 
17 and  reduces Mn(III) to Mn(II) (Figure 20,3). The dioxygen molecule exits from 
the active site and a solvent molecule replaces dioxygen in the axial position of Mn1 
(Figure 20,4). Subsequently, a second molecule of hydrogen peroxide enters the 
active site and bind terminally to Mn1 (Figure 20,5a), or inserts into the cluster core 




bond, two protons and two electrons are donated to the solvent and to the metal 
centre, respectively. This allows the production of two water molecules and the 
oxidation of two Mn(II) to Mn(III) (Figure 20,1)31. 
The heme-containing catalases are characterized by constant rate near to the 
diffusion-controlled turnover(kcat=4·107s-1), on the other hand non-heme manganese 
catalases exhibit much slower kinetics (for L. Plantarum Catalase kcat = 2·105 s-1)31. 
Despite these interesting features, natural CATs and SODs cannot be applied as 
pharmaceutical agents. In fact, they present some limitations due to the low stability 
in solution, short half-life and elevated cost of production32. To help the body fight off 
oxidative stress, antioxidant-rich diet, based on vitamins and polyphenols is still the 
preferred recommendation. Nevertheless, these nutritional antioxidants are non be 
able to react faster with the ROS than the vital biomolecules, so that a high excess 
is required. 
To overcome these limitations, the scientific research, in the past 30 years has been 
focused on the design of small molecules able to act as catalytic antioxidant, in order 
to mimic both SOD and CAT natural enzymes.  The first attempts, focused on the 
elimination of O2•- was introduced in 1979 by Pasternack et al., who used 
metalloporphyrins as SOD mimic33.  
 
Figure 21: First porphyrin studied, with biomimetic activity. 
Successive researches were focused on the synthesis of porphyrin, differently 
substituted with Mn (III) and Fe(III) (Figure 21). Among these, the best Mn porphyrin 




= 3·107 M-1s-1, compared with the value of natural SOD, kcat=2.3·109 M-1s-1. Even if 
the Fe porphyrins display a better SOD-like activity, they are cytotoxic, due to the 
tendency to lose metal ion at low pH, inducing Fenton chemistry 32. 
Recent efforts have been dedicated on the discovery of structures that combine the 
synergistic SOD-CAT activity. While enzymes cannot show both anti-oxidant activity, 
due to their specific proprieties, these can be achieved with synthetic catalyst47. Mn 
complexes with multidentate ligands, as Salen, Shiff’s bases are the most studied in 
the recent years. However, these complexes are soluble in organic solvent, hence 
the main problem is correlated to the low solubility and stability in aqueous media.  
Bonchio and coworkers26 developed new dinuclear Mn(II) complexes, with both 
SOD/CAT activity in physiological condition. The structure is based on a single site 
Mn(III)-heme, implemented with a di-nuclear, non-heme, Mn2(II)L2 catalytic unit 
(Figure 22). The main feature is correlated to “built-in-self-protection” against the 
oxidative risk. The SOD activity, expressed as IC50 values, the initial rate, R0 and the 
ratio kcat/KM are reported in Table 1 and highlight the positive effect in the antioxidant 
activity, expressed by the two units.  
 
 
Figure 22: Structures of A) the ligand, HL, B) the dinuclear Mn (II) complex and C) the dinuclear 





Table 1: SOD/ CAT values obtained for Mn2L2Ac+ and Mn2L2P26+: a) SOD activity based on the cyt c 
assay; IC50 indicates the catalyst concentration required to attain 50% inhibition of the cyt-c reduction; 
Conditions: [xanthine] = 40 μM,  [xanthine oxidase]=0.0053 U/ml, [CytC]=10 μM, [catalase]= 15 μg/ml, 
in  50 mM phosphate buffer, pH=7.8. b) R0 is obtained by linear regression of data within 10 % H2O2 
conversion. Conditions: [catalyst]= 50 μM, [H2O2]=10 mM, 25 °C; Michaelis Menten parameters 
kcat(H2O2)/KM were determined with conditions: [catalyst]= 10 μM, [H2O2]= 0.1-10 mM in BBS 50 mM 
pH=7.8 at 25 °C.  
Complexes IC50(μM)a R0(μmol/min)b kcat/KM(M-1s-1) 
Mn2L2Ac+ 1.04 1620 1245 
Mn2L2P26+ 2.34 2160 1890 
 
Besides manganese, also copper(II) has an important biological. Due to the redox 
behaviour of the Cu(II)/Cu(I) system and the interaction of copper complexes with 
molecular oxygen, biomimetic complexes with interesting ligand have been 
investigated. Riberio et al studied mononuclear copper (II) complex, stabilized by 
N3O ligand donor set, with antioxidant biomimetic activity (Figure 23). They found 
out a low value for IC50 (0.43 μM), indicative of a high SOD-like activity34. 
 
Figure 23: Mononuclear copper(II) complex studied by Riberio et al. 
Others mononuclear copper(II) complexes with relevant SOD and CAT-like activity 
are the ones studied by Pap et al35. In these complexes, the copper (II) centre is 
stabilized by N3 or N3O -donor set ligand (N-methylpropanoate-N,N-bis-(2-
pyridylmethyl)amine= MPBMPA, and N-propanoate-N,N-bis-(2-pyridylmethyl)amine 
= HPBMPA) (Figure 24). The atoms around the copper(II) are in a square-planar 
pyramidal arrangement, where, in the case of HPBMPA, the apical position is 
occupied by the counter ion Cl, while in the complex with MPBMPA, the oxygen of 
the carboxylate group occupies such position. The SOD and CAT values are 





Figure 24: Ligands structure of HBMPA and MPBMPA. 
Table 2: SOD/CAT values obtained for the complexes studied by Pap et al. The IC50 value is 
obtained with CytC assay at pH 7.6, while the CAT experiments were carried out at pH 11. 
Catalysts IC50 (μM) R0(10-4M/s) 
Cu(PBMPA)Cl 1.04 0.35 
Cu(MPBMPA)Cl2 0.62 0.36 
 
Another example, studied in the laboratory where the thesis internship was held, is 
characterized by dinuclear copper(II) complexes, stabilized by N3O-donor set 
ligands. The complexes present an optimal combined superoxide dismutase and 
catalase-like activity, in physiological-like conditions. As regard the structures, the  
complexes are characterized by a distorted octahedral geometry, where each Cu(II) 
atom is coordinated in a facial configuration by the three N atoms of the tetradentate 
ligand, while the phenolate ligands acts as a bridge between the two metal centres26 
(Figure 25). All the three complexes work as artificial SODs in phosphate buffer, at 
pH= 7.8, following a trend that depends on their structure Cu2L12 < Cu2L22 < Cu2L32. 
The same trend is observed also for the CAT-like activity, where the experiments 
were carried out in a borate buffer at pH 7.8. The values relative to the SOD and 








Table 3: SOD/ CAT values obtained for Cu2L12, Cu2L22, Cu2L32. a) SOD activity based on the Cyt c 
assay where radical anions are generated by the xanthine/xanthine oxidase system. Conditions: 
[xanthine] = 40 μM,  [xanthine oxidase]=0.0053 U/ml, [CytC]=10 μM, [catalase]= 15 μg/ml, in  50 mM 
phosphate buffer, pH=7.8; IC50 indicates the catalyst concentration required to attain 50% inhibition 
of the cyt-c reduction; log kcat(O2•–) refers to the rate constant of catalytic superoxide dismutation. b) 
CAT activity is based on oxygen evolution kinetics, monitored by a pressure transducer. R0 where 
obtained by linear regression of data within 10 % H2O2 conversion; Measured in 50 mM BBS, pH 7.8 
at 25 °C. 
Catalysts 
SOD Activitya CAT Activityb 
IC50 (μM) log kcat (O2•–) R0 (μmol O2/s) TON 
Cu2L12 0.40 6.80 0.87 52 
Cu2L22 0.14 7.27 4.4 60 
Cu2L32 0.072 7.55 4.3 60 
 
 
Figure 25: Synthesis and structure of dinuclear complexes studied by Squarcina et al.26 
1.3.4 Multivalent approach 
As already introduced above, in the development of neurodegenerative disorders, 
different factors must be taken into account. The existing approaches focus only on 
one target that determines the neurodegenerative disorders. Hence, the attention is 
moving to multivalent drugs, able to inhibit more than one causes of the AD. 
Multifunctional metal chelators have been tested for both chelating and 
antiaggregation ability. These agents can show good uptake across the BBB, high 




One example is given by the molecules studied by Xingshu Li and coworkers, 
obtained from a combination of resveratrol with the CQ (Figure 26)36.
 
Figure 26: Chemical structures of molecules having bifunctionality: the metal chelation  (blue) and 
Aβ interaction (red)10. 
Others studies are dedicated to the synthesis of molecules that combine the 
chelating and antioxidant activity. BHAPI is an oxidant-triggered prochelator, which 
transforms into a chelator (HAPI) upon reaction with hydrogen peroxide (Figure 27). 
 
Figure 27: Chemical structure of BHAPI and HAPI. The blue colour represents the metal binding 
site, while the red one the antioxidant site10.  
In other works, the attention was pointed on substrates obtained from modified 
Thioflavin-T, a dye used as a marker to detect amyloid deposits in tissues, due to its 
strong affinity for amyloid fibrils. Dedeoglu et al. designed and synthesized 
bifunctional molecule with both amyloid-binding and metal-chelating moieties37 
(Figure 28).  
 




The multitarget approach is complex, but it allows to attack simultaneously the 
different causes of AD. Even if many multifunctional agents have been proposed, 
many other factors need to be studied to obtain a good multitargeting drug. 
1.4 Aim of the thesis  
This work is focused on the synthesis and study of mononuclear and dinuclear  
copper complexes able to inhibit the oxidative stress, mimicking the activity of natural 
enzymes, as well as the formation of Aβ aggregates. The selected N3O-type ligands 
were initially screened for their capability to form copper complexes in aqueous 
mixtures, by evaluating the stoichiometry and biding constants, so to assess their 
potential as copper chelators. The respective complexes were characterized  to get 
information about the structural, spectral and electrochemical features. The 
complexes formed in situ were investigated by potentiometry, in order to understand 
how which species are predominant at physiological pH. Then, their ability as SOD 
and CAT-like was investigated in aqueous media, under physiological-like condition. 
Peroxidase-like activity was also taken into account in order to compare the residual 
oxidant activity with the antioxidant features. Finally, biochemical tests were carried 
out, to verify their capability to interact with amyloid peptides, in order to prevent their 











2. Results and discussion 
The aim of this work is to synthesize small molecules that may mimic the active sites 
of superoxide dismutase and catalase enzymes. Structural modelling of these active 
sites with small coordination complexes is a useful tool to replicate their activity while 
understanding the reaction mechanisms in which they are involved38. This study 
presents the synthesis of mononuclear and dinuclear copper complexes stabilized 
by ligands based on an a N3O donor set, similar to that observed in the active sites 
of the enzymes mentioned. The syntheses of the ligands were carried out exploiting 
a common intermediate, BPMA (bis-(2-pyridylmethyl) amine). Afterwards, the 
chelating ability and the catalytic activity were evaluated, in order to highlight their 
potential antioxidant biomimetic activity. 
2.1 Synthesis and characterization of the intermediate BPMA 
The BPMA (bis-(2-pyridylmethyl) amine) is the common intermediate for the 
synthesis of all the ligands studied. It was obtained according to the procedure 
described by Hamman et al.39, through the reductive amination of pyridine-2-
carboxaldehyde with 2-(aminomethyl)pyridine. In the first step, the mixing between 
the two reactants carried out the formation of the imine, that was reduced in the 
second step by NaBH4 to obtain a brown oil (Figure 29). The BPMA was 
characterized by ESI-MS (+) and by 1H-NMR. Concerning the ESI-MS (+) spectrum, 
it is possible to observe the peak at m/z 200.1, ascribed to the species [HBPMA]+ 
(m/z calc: 200.12). The 1H-NMR shows four signals of the aromatic proton (δ= 8.65 
- 7.18 ppm), one signal for the methylene protons at 4.05 ppm and one for the proton 





Figure 29: reaction steps for BPMA synthesis 
2.2 Synthesis and characterization of ligands and complexes 
2.2.1 Synthesis and characterization of HL1 and Cu(HL1)(ClO4)2 
The reductive amination reaction was exploited for the synthesis of the ligand N-(2-
hydroxylbenzyl)-N,N-bis(2-pyridylmethyl)amine (HL1), according to the procedure 
describe in literature by Connor et al.40. The mechanism involves, at first, the 
formation of an imine between BPMA and salicylaldehyde, which then is reduced to 
a tertiary amine by NaBH3CN (Figure 30) 
 
Figure 30: Reaction mechanism for HL1 synthesis 
The ligand, obtained as a dark red oil was purified with a chromatographic column 





• ESI-MS (+) in CH3CN, that highlights the presence of the species  [H2L1]+ at 
m/z 306.1 (m/z calc. 306.16) (Appendix, chapter 5.1.2); 
• 1H-NMR, that it is crowded from 8.62 to 6.77 ppm, corresponding to the 
aromatic protons zone (Appendix, chapter 5.1.2); 
• FT-IR spectroscopy (<1800 cm-1, Figure 31), where it is possible to observe 
the sharp signals relative to the C-H stretching of the aromatic groups (761 
cm-1), the C-N stretching vibration characteristic of the tertiary amine at 1374-
1369 cm-1, a band at 1242 cm-1 typical of the C-OH stretching of the phenolic 
group and the stretching of C C and C N of the aromatic ring from 1586 
cm-1 to 1435 cm-1; 
 
Figure 31: FT-IR spectrum of HL1 from  <1800 cm-1 (KBr) 
• UV-vis spectrum (Figure 32) highlights the presence of a band, with the 
maximum at 261 nm, typical of the π→π* transition of the aromatic group. It 
is possible to observe two smaller bands at 256 nm and 267 nm and a 





Figure 32: UV-vis spectra of the ligand HL1 MeOH(5%v/v)/H2O, 0.1 mM 
HL1 is an N3O ligand, that in the mononuclear complex can coordinate the metal 
centre through the two pyridine nitrogen, the nitrogen of the tertiary amine and the 
oxygen of the alcoholic group. The synthesis of the mononuclear complex was 
carried out blending equimolar solutions of the ligand (yellow solution) and Cu(ClO4)2  
(light blue solution) in MeOH or CH3CN (Figure 33). When the two solutions were 
mixed, the resulting solution appeared blue. For the crystallization, the slow 
evaporation and liquid / vapour diffusion methods were used. 
 






The blue crystals obtained were characterized by: 
• ESI-MS (+) in CH3CN, which shows the characteristic peak at m/z 367.1 , 
relative to the species [CuL1]+ (calc: 367.07) and a peak at m/z 403.1 (calc: 
403.05), due to the adducts with Cl-  [CuHL1Cl]+ (Appendix, chapter 5.1.3); 
• Elemental analysis (calc: C, 37.79; H, 3.84, N, 6.96; found: C, 37.25; H, 3.78; 
N, 7.18) that highlights the presence of two molecules of water in the complex 
[Cu(HL1)(ClO4)2]·2H2O; 
• FT-IR spectroscopy (< 1400 cm-1, Figure 34), where it is possible to observe 
an intense band at 1101 cm-1 and a sharp one at 622 cm-1, probably due to 
the stretching and the bending of the metal centre with the atoms of the ligand; 
 
 
Figure 34: FT-IR spectrum of the complex Cu(HL1)(ClO4)2 from  < 1400 cm-1 (KBr), the signal at 
700 cm-1 is due to electrical spike. 
• UV-vis spectroscopy (Figure 35) highlights the presence of one band at 255 
nm relative to the π→π* transition of the aromatic groups and a band at 660 






Figure 35: UV-vis spectra of the complex Cu(HL1)(ClO4)2 in MeOH(5%v/v)/H2O, 0.1 mM; zoom: 
band at 660 nm of the complex at the concentration 1.5 mM, in MeOH(5%v/v)/H2O. 
In solution the mononuclear complex studied exhibits a distorted square-pyramidal 
arrangement. Complexes with this geometry, indeed, presents a single broad d-d 
absorption band at about 700 nm. Indeed, the UV-vis spectrum of Cu(HL1)(ClO4)2 
points out the presence of a band at 660 nm, that confirms this arrangement.  
The complex structure was also solved at the solid state by X-ray diffraction. The 
single-crystal X-ray diffraction study was carried out only for the crystals grown from 
CH3CN/Et2O. Crystals grown from MeOH/Et2O, instead, decomposed too quickly 
once exposed to the air. The crystallographic study revealed that the crystallization 
solvent always enters the coordination sphere of the Cu (II) ions, occupying one of 
the four equatorial positions. Therefore, the crystallized complex is best formulated 
as [Cu(HL1)(CH3CN)ClO4](ClO4)·CH3CN.  
The crystal structure of this compound is already present in literature, with acetone 
as the crystallization solvent41. The monomeric structure of 
[Cu(HL1)(CH3CN)ClO4](ClO4)·CH3CN contains a central copper metal atom with a 





Figure 36: Crystal structure of the complex [Cu(HL1)(CH3CN)ClO4](ClO4)·CH3CN. 
The square plane is defined by the three nitrogen atoms of the ligand (N1, N2, N3) 
and by the nitrogen atom of the solvent (N1S), CH3CN. The oxygen of the alcoholic 
group of the ligand is in the apical position, while a perchlorate anion occupies the 
opposite position. The geometry is distorted, since the atoms bound to the copper 
metal centre do not lay in the equatorial plane and the bonds between the copper 
and the oxygens in the apical position are not perfectly perpendicular to the 
equatorial plane. Main bond lengths are shown in Table 4. 
Table 4: Selected bond lengths of [Cu(HL1)(CH3CN)ClO4](ClO4)·CH3CN 












2.2.2 Synthesis and characterization of HL5 and Cu(HL5)(ClO4)2 
The synthesis of the 2-{[Bis(pyridin-2-ylmethyl)amino]methyl}-6-methoxyphenol 
(HL5) was carried out following the same procedure used for the ligand HL1. In this 
case, the reagent employed for the reductive amination was the o-vanillin, that 
reacted with the secondary amine group of the BPMA. The imine formed was 
reduced to tertiary amine by NaBH3CN (Figure 37). The product was purified with a 
chromatographic column, using DCM : MeOH 8:2, saturated with NH4Cl, as eluent, 
in order to obtain a dark orange oil, with 44% yield. 
 
Figure 37: Reaction mechanism of the ligand synthesis HL5 
The ligand was characterized by: 
• ESI-MS (+) in CH3CN, that shows one peak relative to the protonated species 
[H2L5]+ at m/z 336.2 (calc: 336.17) (Appendix, chapter 5.1.4);  
• 1H-NMR spectrum points out the signal at 3.90 ppm relative to the methoxy 
group, besides the peaks from 8.65 to 6.66 ppm, due to the protons on the 
aromatic rings (Appendix, chapter 5.1.4); 
• FT-IR spectroscopy (<1800 cm-1, Figure 38), in which it is possible to 
observe the same signals of HL1, due to the similar structure: the C-H 




characteristic of the tertiary amine at 1373-1387 cm-1 and the stretching of      
C C and C N of the aromatic rings from 1585 cm-1  to 1433 cm-1; the 
specific peak of this ligand is the C-O stretching of the methoxy group at 1249 
cm-1. 
 
Figure 38: FT-IR spectrum of HL5 from  <1800 cm-1 (KBr) 
• UV-vis (Figure 39), that points out a maximum absorption at 261 nm, due to 
π→π* transition of the aromatic group and the shoulders 256, 267 and 284 nm. 
 
Figure 39: UV-vis spectra of the ligand HL5 MeOH(5%v/v)/H2O, 0.1 Mm 
The synthesis of the mononuclear complex was carried out with the same procedure 




40). The blue crystals were obtained through the slow evaporation and liquid/ vapour 
methods.  
 
Figure 40: Reaction for the synthesis of the mononuclear complex Cu(HL5)(ClO4)2 
The crystals were analysed by: 
• ESI-MS (+) in CH3CN, which shows two characteristic peak at m/z 397.1  
(calc: 397.08) and m/z 497.0 (calc: 497.04) relative to the species [CuL5]+ 
and [CuHL5(ClO4)]+, respectively (Appendix, chapter 5.1.5); 
• Elemental analysis points out the presence of one molecule of water (calc: C, 
39.01; H, 3.76; N, 6.82; found: C, 39.06; H, 4.00; N, 6.86, relative to the 
species [Cu(HL5)(ClO4)2]·H2O).  
• FT-IR spectroscopy (< 1800 cm-1,Figure 41), where it possible to observe, 
besides the signals relative to the ligand, a broad band at 1101 cm-1 and a 
sharp one at 625 cm-1, due to the stretching and the bending of the copper 
with the atoms bounded. 
• UV-vis spectroscopy (Figure 42) highlights the presence of one band at 256 
nm relative to the π→π* transition of the ligand aromatic groups and a 




absorption. The band at 662 nm is characteristic of a complex with a central 
metal copper in a distort square-pyramidal arrangement. 
 
Figure 41: FT-IR spectrum of the complex Cu(HL5)(ClO4)2 from  < 1800 cm-1 (KBr) 
 
 
Figure 42: UV-vis spectra of the complex Cu(HL5)(ClO4)2 in MeOH(5%v/v)/H2O, 0.1 mM; zoom: 
band at 662 nm of the complex at the concentration 1.5 mM, in MeOH(5%v/v)/H2O. 
The geometry of the complexes was also studied by single-crystal X-ray diffraction. 




MeOH/Et2O. In the latter case, the experiment was carried out at 150K, in order to 
delay the crystal decomposition.  
Since the crystallization solvent always enters the coordination sphere of Cu (II), 
occupying one of the equatorial position, as described for the complex with HL1,  the 
crystallized complexes are formulated as  [Cu(HL5)(CH3CN)ClO4](ClO4) and 
[Cu(HL5)(MeOH)ClO4](ClO4). 
The monomeric structures of [Cu(HL5)(CH3CN)ClO4](ClO4) and 
[Cu(HL5)(MeOH)ClO4](ClO4) contain a central copper metal atom with a distorted 
octahedral arrangement (Figure 43). The square plane is defined by the three 
nitrogen atoms of the ligand (N1, N2, N3) and by the nitrogen atom of the solvent 
(N1S), in the case of the first structure, while for the crystal grown from MeOH/Et2O, 
the forth atom in the square plane is the oxygen (O1S), relative to the methanol. 
 
Figure 43: Crystal structure of [Cu(HL5)(CH3CN)ClO4](ClO4) (left) and [Cu(HL5)(MeOH)ClO4](ClO4) 
(right). 
The oxygen of the alcoholic group of the ligand and a perchlorate anion occupy the 
apical positions. The distortion of the geometry is due to the atoms bound to the 
copper metal centre, which do not lay in the equatorial plane and to the bonds 
between the copper and the oxygen in the apical position that are not perfectly 




Table 5: Selected bond lengths of [Cu(HL5)(CH3CN)ClO4](ClO4) and [Cu(HL5)(MeOH)ClO4](ClO4) 
Atoms 
Distances (Å )for 
[Cu(HL5)(CH3CN)ClO4](ClO4) 
Distances (Å) for 
[Cu(HL5)(MeOH)ClO4](ClO4) 
Cu1-N1 2.019 2.027 
Cu1-N2 1.978 1.968 
Cu1-N3 1.975 1.979 
Cu1-N1S/O1S 1.981 1.985 
Cu1-O1 2.485 2.470 
Cu1-O1P 2.575 2.504 
 
2.2.3 Synthesis and characterization of HBPMP and Cu2(BPMP)(H2O)2(ClO4)3 
The ligand HBPMP was synthesized through an alkylation reaction of the secondary 
amine (BPMA) with 2,6-bis(chloromethyl)-4-methylphenol, according to the 
procedure described by Torelli et al.42. The mechanism is illustrated in the Figure 44. 
 
Figure 44: Reaction mechanism for the synthesis of HBPMP 
The product was purified with a chromatographic column, using a mixture of   





The ligand was characterized by: 
• ESI-MS (+) in CH3CN, that shows the peak at m/z 531.2 (calc: 531.29) 
ascribed to the species [H2BPMP]+ (Appendix, chapter 1.5.6); 
• 1H-NMR, that is crowded from 8.68 to 7.19 ppm, corresponding to the 
aromatic zone (Appendix, chapter 1.5.6); 
• FT-IR spectrum (<1800 cm-1, Figure 45), points out the sharp signals relative 
to the C-H stretching of the aromatic groups at 756 cm-1, the C-N stretching 
vibration characteristic of the tertiary amine at 1362-1374cm-1, a band at 1232 
cm-1 typical of the C-OH stretching of the phenolic group and the stretching 
of C C and C N of the aromatic ring from 1586 cm-1  to 1430 cm-1. 
 
Figure 45: FT-IR spectrum of HBPMP from  <1800 cm-1 (KBr) 
• UV-vis spectroscopy (Figure 46), that highlights the presence of a band 
characteristic of the π→π* transition of the aromatic group at 261 nm, with two 





Figure 46: UV-vis spectra of the ligand HBPMP MeOH(5%v/v)/H2O, 0.1 mM 
Concerning the synthesis of the dinuclear complex [Cu2(BPMP)(H2O)2](ClO4)3, the 
procedure of Torelli et al.42 was adopted with some modification (Figure 47). The 
ligand HBPMP was dissolved in a solution of water and acetone, after, a double 
amount of copper perchlorate was added dropwise to obtain a brown solution. The 
dark green crystals were obtained with the interface and slow evaporation technique.  
 
Figure 47: Reaction of the [Cu2(BPMP)(H2O)2](ClO4)3 synthesis 
The crystals were studied by: 
• ESI-MS (+) in H2O, that shows the peaks at 727.2 (calc: 727.12); and 745.2 
(calc: 745.18) attributable to the species [Cu(BPMP)(H2O)2(ClO4)]+ and 




• Elemental analysis differs slightly to the calculated values due to the presence 
of four molecule of water (calc: C, 37.28; H, 4.27; N, 7.90; found: C, 37.97; H, 
4.11; N, 7.69, attributable to the species [Cu2(BPMP)(H2O)2(ClO4)3]·4H2O ). 
• FT-IR spectroscopy (< 1800 cm-1, Figure 48), where it is possible to observe, 
beside the signals relative to the ligand, a broad band at 1096 cm-1 and a 
sharp one at 625 cm-1, due to the stretching and the bending of the copper 
with the atoms bounded. 
 
Figure 48: FT-IR spectrum of the complex [Cu2(BPMP)(H2O)2][(ClO4)3] from  < 1800 cm-1 (KBr) 
• UV-vis spectrum (Figure 49) points out a band at 255 nm and a shoulder at 
303 nm, due to the π→π* transition of the ligand aromatic group, while at 460 
nm it is possible to notice a band, most probably due to CT (L→M) transition 





Figure 49: UV-vis spectra of the complex [Cu2(BPMP)(H2O)2][(ClO4)3] in H2O, 0.1 mM; zoom: band 
at 460 nm and 700 nm of the complex at 1.5 mM concentration. 
In the dinuclear complex studied, each copper atom is pentacoordinated, bound by 
three nitrogen atom: one from the tertiary amine and two from pyridines, and by two 
oxygen atoms from the phenoxo bridge and a terminal water molecule. The X-ray 
structure, reported in literature42 points out a square pyramidal distorted geometry, 
whose apical position is occupied by the bridging phenoxo oxygen (Figure 50). The 
square plane is defined by the three nitrogen atoms of the ligand (N1,N2,N3) and by 
the oxygen of the water molecule (O2). The copper atoms lies 0.21 Å out of the basal 
plane toward the apical oxygen of the phenoxo group (O1).The two copper atoms 
are on different sides of the phenolate plane. Due to the oxygen of the phenoxo 
group in the apical position of both the copper atoms, the intermetallic distance is 
4.139Å. This distance is the longest one observed for a singly phenoxo-bridged 
dicopper (II) complex in which both copper are in tetragonal pyramidal environment. 
The distorted square pyramidal geometry is also confirmed by UV-vis spectra since 
five-coordinate square pyramidal Cu(II) complexes exhibit a single broad d→d 





Figure 50: X-ray structure of the complex [Cu2(BPMP)(H2O)2][(ClO4)3]43 
The principal interatomic distances are reported in the Table 6. 
Table 6: principal interatomic distances for the complex [Cu2(BPMP)(H2O)2][(ClO4)3] 
















2.3 Chelating ability of the ligands 
The coordination ability was evaluated through a titration of the ligands with 
increasing amount of Cu(II) solution. As regarding the ligands HL1 and HL5, the 
experiments were carried out with two different concentration of the ligands, 0.1 mM 
and 1.5 mM, whereby the last concentration is suitable to observe the changes in 
the d-d bands. While, for HBPMP, due to the precipitation of the ligand at high 
concentration, the titration was recorded only at 0.1 mM . 0.1 eq of copper (II) were 
added in each aliquot (Experimental section, chapter 4.6). The formation of the 
complex is evaluated by UV-vis spectroscopy, observing the absorbance changes. 
For all the three ligands, the spectra show an increase in the absorbance of the UV-
vis band due to the π→π* transition of the aromatic rings (“hyperchromic” effect) and 
a simultaneous change in the shape of the bands (Figure 51, Figure 52, Figure 53). 
In the spectra of HL1 and HBPMP it is possible to observe a shift to lower wavelength 
(blue shift). Moreover, the titration of HL1 highlights the presence of two isosbestic 
points (Table 7), that suggest an equilibrium between the ligand and the other 
species, formed during the addition of copper (II). The spectra of HL1 and HL5 at 
1.5 mM points out an increase in the absorbance of the d→d band, due to formation 
of the complex. 
Table 7: Maximum absorptions of π→π* and d→d bands, blue shift and isosbestic point, obtained 
from the titration of the ligands with Cu(II). Conditions for the π→π* bands [ligand]= 0.1mM; 
[copper(II)]=0.01M; for the d→d, only for HL1 and HL5, [ligand]= 1.5mM, [copper(II)]= 0.15M. 2.5μL 




λmax  d→d 
(nm) 
Blue shift (nm) 
Isosbestic points 
(nm) 
HL1 261 665 5 266, 269 
HL5 260 661 - - 






Figure 51: UV-vis spectra collected during HL1 titration: spectra A) shows π→π* band, B) d→d band. 
The titration was carried out using the following concentration: 0.01M Cu(II) in water and 0.1 mM of 
the ligand, for the π→π* band, and 0.15M Cu(II) in water and 1.5mM of the ligand. The solutions of 
the ligand were obtained from a stock solution in MeOH. 
 
Figure 52: UV-vis spectra of HL5 titration: spectra A) shows π→π* band, B) d→d band. The titration 
was carried out using the following concentration: 0.01M Cu(II) in water and 0.1 mM of the ligand, for 
the π→π* band, and 0.15M Cu(II) in water and 1.5mM of the ligand. The solutions of the ligand were 





Figure 53: UV-vis spectra of HBPMP titration: spectra A) shows π→π* band, B) d→d band. The 
titration was carried out using the following concentration: 0.01M Cu(II) in water and 0.1 mM of the 
ligand. The solutions of the ligand were obtained from a stock solution in MeOH. 
 
 
Figure 54: graph of the relative absorbance variation with number of Cu(II) equivalent, obtained from 
the titration of HL1 (blue), HL5 (red) and HBPMP (green). For HL5 and HL1 at λmax of d→d band, 
HBPMP at 290 nm. 
The graph “Abs at λmax vs Cu(II) equivalent” highlights the formation of 1:1 complex 
for the ligands HL1 and HL5, while for HBPMP the formation of dinuclear complex is 




absorbance at the maximum absorption (d→d), until reaching the plateau, when the 
ratio between Cu(II) and the ligands is 0.9:1. On the other hand, for the dinuclear 
complex, the increase of absorbance has been evaluated at 290 nm, until reaching 
the plateau when the ratio between Cu(II) and the ligand is 1.5:1 (Figure 54). The 
differences with respect to the expected ratios, 1:1 and 2:1, are likely due to the 
occurrence of different protonation states for the ligands (see next paragraphs).  
The Benesi-Hildebrand equation (19) was applied for the calculation of the binding 







 +  
1
(Amax − A0)
   (19) 
 
Figure 55: Graphic for the calculation of the binding constant of HBPMP with Cu(II) 
Figure 55 shows the trend achieved for the ligand HBPMP, the behaviour of the 
ligands HL1 and HL5 is the same, but with different slopes and intercepts. The 




Table 8: Binding constants of HL1, HL5 and HBPMP derived through the Benesi-Hildebrand 
method 





The highest binding constant value is the one of HBPMP, this ligand is the best 
chelating agent for the copper (II). HL1 and HL5 have values of the same order of 
magnitude, but the binding constant of HL1 is higher than the one of HL5. However, 
this values are lower than the ones observed for the free SOD with Cu (II), which 
range from 105 to 106 M-1 44. 
The stoichiometry of the complexes generated in situ was better evaluated through 
the Job’s Plot (Experimental section, chapter 4.6). The Job’s plot confirms the 
formation of the 1:1 complex for HL1 and HL5, since the maximum absorption value 
is obtained for equal molar fractions of ligand and Cu (II). On the other hand, for 
HBPMP the maximum is shifted to higher molar fractions of Cu(II). This is a typical 
behaviour expected for a dinuclear complex. For the HBPMP, a lower overall 
concentration was used, moreover the data were acquired when the Cu (II) 
equivalents were equal to 0.5, due to the precipitation of the free ligand at higher 





Figure 56: Job’s plot at λmax of d→d band generated from the formation of copper complex with HL1 
(blue), HL5 (red), HBPMP (green). Solution concentration 0.75 mM of copper (II) and 0.75 mM of the 
ligands HL1 and HL5. For HBPMP the conditions were 0.35 mM of Cu (II) and 0.35 mM of ligand. 
The solution of copper was made in water, while the ligands solutions were obtained from a stock 
solution in methanol.  
The behaviour of the ligand and the corresponding in situ-formed complexes were 
studied as a function of pH by UV-Vis spectroscopy. As regards the spectrum of the 
ligand HL1, it is possible to observe a decrease of absorbance at 263 nm 
(hypochromic effect) and a shift of the π→π* band to lower wavelength (261 nm), 
increasing the pH. Moreover, when the pH is 9.72, a shoulder and a band appear at 
299 nm and 379 nm, respectively. For the study of in situ-formed complex the ratio 
used is Cu (II): HL1 1:1.2, to avoid the copper precipitation. Increasing the pH till 
7.72 the absorbance of the band at 261 nm decrease, then increases at  basic pH. 
From pH 7.72 it is possible to observe the formation of a shoulder at 296 nm. At 
basic pH a band appears at 473 nm, and then disappears at pH 9.72, with the 





Figure 57: A) pH-metric titration of the ligand HL1, B) zoom to highlight the band at 379 nm; C) pH-
metrical titration of in situ-formed complex Cu:HL1 1:1.2, D) zoom to highlight the bands at 473 nm 
and 391 nm. The titrations start from pH about 2.7 to pH 10.7, each colour variation represents the 
change in pH of one unit, using a solution of NaOH. The solutions were in DMSO (5% 
v/v)/H2O(HCl/KCl), 0.76mM. 
The pH-metrical titration of the ligand HL5 points out a hypochromic effect till pH 
5.67, then, at pH higher, the absorbance increases. When the pH is 5.67 a shoulder 
appears at 283 nm and at basic pH there is a band at 391 nm. As regards in situ-
formed complex, the ratio adopted is Cu:HL5 1:1.2. The trend at 261 nm is the same 
as the one observed for the ligand. Moreover, it is possible to notice that the shoulder 
at 285 nm, present at low pH  shifts to 300 nm at basic pH. At 464 nm there is a band 
from pH 6.68 to 9.69, that then moves to 418 nm when the pH is higher (Figure 58). 
Concerning the ligand HBPMP, it is possible to observe a decrease of absorbance 
at 261 nm, increasing the pH. Furthermore, when the pH is about 5, a shoulder 
appears at 290 nm, while the band at 350 nm moves to higher wavelength. The 
spectra were collected till pH of about 9, because of the precipitation of the ligand. 
For the study of in situ-formed dinuclear complex the ratio used is HBPMP:Cu 1:2. 
Increasing the pH, a shoulder and a band appear respectively at 299 and 397 nm, 





Figure 58: A) pH-metric titration of the ligand HL5, B) zoom to highlight the band at 391 nm; C) pH-
metrical titration of in situ-formed complex Cu:HL5 1:1.2, D) zoom to highlight the bands at 464 and 
418 nm. The titrations start from pH about 2.7 to pH 10.7, each colour variation represents the change 
in pH of one unit. The solutions were in DMSO (5% v/v)/H2O(HCl/KCl), 0.71mM. 
 
Figure 59: A) pH-metric titration of the ligand HBPMP, B) zoom to highlight the band at 350 nm; C) 
pH-metrical titration of in situ-formed complex Cu:HBPMP  2:1, D) zoom to highlight the bands at 397 
and 466 nm. The titrations start from pH about 2.7 to pH 10.7, each colour variation represents the 
change in pH of one unit. The solutions were in DMSO (5% v/v)/H2O(HCl/KCl), 0.43mM. 
The ligands and complexes pH-metrical titration points out that the pH variation 
causes the formation of different species in solution. To better understand the 
species generated at different pH, potentiometric titrations were carried out. These 
experiments were performed in collaboration with the research group of the 
Professor Justyna Brasun at the Medical University of Wroclaw (PL). The titrations 
allowed the construction of speciation curves, that is, curves highlighting the 
formation of the species generated at different pH. As regards the ligands, the 




pH. Through the addition of 14 μL of NaOH 0.1M to a ligand solution (0.1mM in 
DMSO 5%(v/v)/H2O (HCl/KCl), initial pH 2.7), the distribution curves (Figure 60 and 
Figure 61) and the acid associations constants were calculated (Table 9 and Table 
10). 
As regard the  ligands HL1 and HL5, Lx- is the ligand with the deprotonated phenol, 
HLx is the original ligand, [H2Lx]+ is the ligand with the tertiary amine protonate, while 
[H3Lx]2+ and [H4Lx]3+ represent the ligand with pyridine nitrogens protonated (Table 
9). Concerning the ligand HBPMP, L- is the ligand with the deprotonated phenol, HL 
is the original ligand, [H2L]+ and [H3L]2+ are the species with the tertiary ammine 
protonated, while H5L represents the ligand with pyridine nitrogen protonated (Table 
10). These attributions were made by comparing the data obtained experimentally 
with those present in the literature, for similar compounds45,46. 
Table 9: Overall (log βi) and stepwise (log Ki) protonation constants of the ligands HL1 (x=1) and HL5 











Lx- + H+  HLx 10.01 10.52 Lx -+ H+  HLx 10.01 10.52 
Lx- + 2H+  [H2Lx]+ 16.23 16.76 HLx + H+  [H2Lx]+ 6.22 6.24 
Lx-+ 3H+  [H3Lx]2+ 21.09 21.74 [H2Lx]++H+  [H3Lx]2+ 4.86 4.98 
Lx- + 4H+  [H4Lx]3+ 24.52 25.41 [H3Lx]2++H+ [H4Lx]3+ 3.43 3.67 
 
Table 10: Overall (log βi) and stepwise (log Ki) protonation constants of the ligand HBPMP, obtained 
from potentiometric titration.  
Equilibrium reaction log βi Equilibrium reaction log Ki 
L- + H+  HL 7.01 L + H+  HL 7.01 
L- + 2H+  [H2L]+ 12.89 HL + H+ [H2L]+ 5.88 
L- + 3H+  [H3L]2+ 17.40 [H2L]+ + H+ [H3L]2+ 4.51 
L- + 4H+  [H4L]3+ 20.95 [H3L]2+ + H+ [H4L]3+ 3.55 





Figure 60: Speciation curves for the ligands HL1 and HL5. Conditions: [ligands]= 0.07mM in DMSO 
(5%v/v)/(H2O/HCl,KCl,  starting pH=2.7). 
 
Figure 61: Speciation curve for the ligand HBPMP. Contion: [ligands]= 0.043mM in DMSO 
(5%v/v)/(H2O/HCl,KCl; starting pH=2.7). 
The trends highlight in the speciation curves is quite similar for both HL1 and for HL5  
(Figure 60). Both ligands present high stability at pH 8, where the main species is 
the original ligand HL. While only a small amount is protonated at physiological pH. 
As regards HBPMP, the speciation curve shows that the main species at  pH 7.4 is 
HL, while the prevailing form at pH at about 5.5 is the one with one tertiary amine 
protonate (Figure 61). In this case the potentiometric titration was carried out till pH 




agreement with the pH-metrical titration describe above, in fact at about pH 8 it is 
possible to observe the formation of a shoulder at ~290 nm, attributable to the 
phenolic group (Figure 57, Figure 58, Figure 59). 
From the potentiometric titration of solutions with the copper (II) and the ligands, with 
NaOH, the speciation curves of in situ-formed complexes were obtained and the acid 
association constants were calculated (Table 11, Table 12). For the ligands HL1 and 
HL5 the ratio used is 1.2:1 (ligand : copper), whereas for the HBPMP the 1:2 ratio 
(ligand:copper)  was adopted.   
Table 11: Overall (log βi) and stepwise (log Ki) protonation constants of in situ- formed complexes 
with HL1 (x=1) and HL5 (x=5), obtained from potentiometric titration.  








[CuH2Lx]3+ 23.54 23.16 5.09 5.42 
[CuHLx]2+ 18.45 17.74 6.94 6.38 
[CuLx]+ 11.51 11.36 9.47 9.12 
[Cu(OH)Lx] 2.04 2.24 10.40 10.73 
 
Table 12: Overall (log βi) and stepwise (log Ki) protonation constants of in situ-formed complex with 
HBPMP, obtained from potentiometric titration.  
Species log (βi) log (Ki) 
[CuH3L]4+ 22.60 3.59 
[CuH2L]3+ 19.01 4.81 
[CuHL]2+ 14.20 6.32 
[CuL]+ 7.88 8.72 
[Cu(OH)L] -0.84 11.37 
[Cu(OH)2L]-1 -12.21 0 
[Cu2H2L]5+ 23.47 4.28 
[Cu2HL]4+ 19.19 5.44 
[Cu2L]3+ 13.75 8.38 




The species considered in the final model were obtained by taking into account the 
total set of data resulting from the different titrations. In addition to the ligand 
deprotonation steps, two additional deprotonation had to be included, probably 
accounted for the deprotonation of water molecules bound to the copper ions. 
The constants for the mononuclear complexes, presented in table Table 11, allow 
the construction of speciation curves (Figure 62). At pH 3.5 the predominant species 
is [CuH2L]3+ relative to the copper complex with a protonated ligand. Upon increasing 
the pH the formation of [CuHL]2+ is favoured (copper complex with the original 
ligand). At pH 7.8, the mononuclear complexes are in the form [CuL]+ while the 
species [CuHL]2+ is 11% and 5% for HL1 and HL5, respectively. Above pH 9 the 
formation of the species [Cu(OH)L] and [Cu(OH)2L]-, due to the loss of one and two 
protons by an external source, probably a water molecule, is observed45.   
 
Figure 62: Speciation curves for the situ-formed complexes ligand : copper (II) 1.2:1. A) with ligand 
HL1, B) with the ligand HL5. The solutions are 0.7mM in DMSO (5%v/v)/(H2O/HCl,KCl; starting 
pH=2.7). 
Concerning the dinuclear complex, the speciation curve (Figure 63), obtained from 
the constants show in Table 12 highlights a different behaviour. At pH 3.5, the 
prevalent species in the dinuclear one, with the protonated ligand ([Cu2H2L]5+). Upon 
increasing the pH, the formation of [Cu2HL]4+ (copper complex with the original 
ligand) occurs. At pH 7.8 the more stable form at is [Cu2L]3+. Above pH 9 the 
formation of the species, due to the loss of one [Cu2(OH)L]2+ and two 
[Cu2(OH)2L]+protons by a water molecule, is observed45. The mononuclear species 





Figure 63: Speciation curves for the situ-formed complexes ligand : copper (II) 1:2. The solution is 
0.7mM in DMSO (5%v/v)/(H2O/HCl,KCl; starting pH=2.7). In the legend the monuclear species are 
indicated.  
In all cases the data simulations, realized with the software Hyperquad 2008 is in 
agreement with the formation of mononuclear complexes for HL1 and HL5, and 







































2.4 Catalytic activity of the complexes 
The antioxidant activity is the main catalytic activity of the complexes studied. In 
order to evaluate this propriety, their redox proprieties were initially examined. Then, 
the superoxide dismutase and catalase like-activities were studied, to verify their 
ability to work as ROS scavenging. Finally, the peroxidase activity was considered, 
using two models substrate. 
2.4.1 Cyclic voltammetry  
The challenge is to design stable metal complexes with low molecular weight, that 
display a suitable redox cycle for the metal ion. In fact, the copper centre has to 
catalyse the disproportionation of superoxide radical. At the beginning, the redox 
potentials of the species were evaluated through cyclic voltammetry. By means of 
this technique, it is possible to appraised the reduction potential of Cu2+/Cu+, which 
is an important factor in the SOD activity. The potential for the monoelectronic 
reduction of the superoxide anion to hydrogen peroxide is equal to 0.89 V, while the 
potential for the superoxide anion radical reduction is equal to - 0.16 V. Therefore, 
the metal ion redox potential has to lie between the potential for oxidation (-0.16 V 
vs. NHE) and reduction (0.89 V vs. NHE) of superoxide radicals (Figure 64). The 
copper ion must also be able to cycle between the Cu(II) and Cu(I) oxidation states 
faster than the rate of the spontaneous disproportionation of superoxide radical. As 
well the ligand has an important role, because it must have high affinity for both the 
reduced and oxidized state of the metal to obtain complexes that are stable under 
physiological conditions, in order to avoid the release of metal during the redox 
cycling. Finally, at least one coordination site must be available for binding of the 





Figure 64: Redox potentials for the reduction and oxidation of superoxide radical anion and for 
several natural SOD in aqueous solution at pH 7.0.The reduction potential of natural SODs is between 
0.2 and 0.4V47. 
Cyclic voltammograms of the mononuclear complexes were collected at the 
concentration of 50 mM in a mixture of CH3CN 5%(v/v)/H2O (phosphate buffer 10 
mM, 100 mM NaCl, pH 7.8). Concerning the dinuclear complex, the concentration of 
the catalyst was 0.25 mM, and the solution was made in PBS, because of the high 
solubility of the complex in aqueous media. The voltammogram were collected using 
a glassy carbon (GCE) electrode as a working electrode, a counter electrode (Pt) 
and a reference electrode Ag/AgCl (NaCl 3M). The measurements were carried out 
between 400 and -500 mV, with a scan rate equal to 50 mV/s. The voltammogram 
of the mononuclear complexes were also recorded at different scan rate: 100, 200, 
400 and 800 mV/s. The characteristic values of the cyclic voltammogram were 
reported in  
Table 13, the potentials were referred to the NHE (VNHE= VAg/AgCl + 0.210 V).  
As regards the mononuclear complexes, it is possible to distinguish two peaks, the 
anodic one, relative to the oxidation (towards positive potential), and the cathodic 
peak of the reduction (towards negative potential). The curves shows the mono-




the values ΔE = Epc - Epa are all higher than 59 mV. For each complexes, the values 
of E1/2 =  
Epc+Epa
2
  can be found within the limits suitable for superoxide dismutation. 
Table 13: Epc, Epa, E1/2, ΔE, │ia/ic│ values obtained from the cyclic voltammograms of the complexes 
Complexes Epc (V) Epa (V) E1/2 (V) ΔE (V) │ia/ic│ 
Cu(HL1)(ClO4)2 -0.177 -0.092 -0.135 -0.085 0.61 
Cu(HL5)(ClO4)2 -0.202 -0.096 -0.149 -0.106 0.52 
Cu2(BPMP)(H2O)2(ClO4)3 - -0.127 - - - 
  
 
Figure 65: Cyclic voltammograms of the complex Cu(HL1)(ClO4)2  A) recorded at scan rate 50 mV/s; 
B) recorded at scan rates: 50 mV/s, 100 mV/s, 200 mV/s, 400 mV/s, 800mV/s. [Cu(HL1)(ClO4)2] = 
0.50 mM, in CH3CN 5%(v/v)/H2O (PBS 10 mM, 100 mM NaCl, pH 7.8). 
 
Figure 66: Cyclic voltammograms of the complex Cu(HL5)(ClO4)2  A) recorded at scan rate 50 mV/s; 
B) recorded at scan rates: 50 mV/s, 100 mV/s, 200 mV/s, 400 mV/s, 800mV/s. [Cu(HL1)(ClO4)2] = 
0.50 mM, in CH3CN 5%(v/v)/H2O (PBS 10 mM, 100 mM NaCl, pH 7.8). 
The graph “ip (μA) vs √𝑣𝑠𝑐𝑎𝑛 (𝑚𝑉/𝑠)" for the mononuclear complexes underlines a 




agreement with the Randles-Sevcik law for reversible process, where the transport 
phenomena occur with diffusion regime. On the other hand, the ratio between the 
peaks currents(ipa/ipc) is less than one, probably due to the change in the 









Regarding the dinuclear complexes, the curve highlights an irreversible process. In 
fact, it is possible to distinguish only the anodic peak at -0.127V (Figure 68).  
 
Figure 68: Cyclic voltammogram of the complex Cu2(BPMP)(H2O)2(ClO4)3 recorded at 50 mV/s. 
[Cu2(BPMP)(H2O)2(ClO4)3] = 0.25 mM, in H2O (PBS 10 mM, 100 mM NaCl, pH 7.8). 
Figure 67: graph “ip  vs √𝒗𝒔𝒄𝒂𝒏 ” obtained from the cyclic voltammograms of the complexes with HL1 




The anodic and cathodic curves are attributable to the redox couple Cu(II)/Cu(I), 
whose reduction potential are well defined only for the mononuclear complexes with 
HL1 and HL5. These values are within the limit, described in Figure 64, hence the 
complexes should be able to act as antioxidant compound. However, the redox 
potential is not the only factor to take in account in the study of antioxidant activity, 
because the SOD activity depends strongly on the geometry around the copper ion48. 
To verify the absence of metallic copper on the electrode surface, due to the 
decomposition or release of Cu(II) during the redox process, the unpolished tests 
were carried out. The tests confirm the stability of the species in solution, since no 
residual band was observed.   
2.4.2 Superoxide dismutation-like activity 
In order to have good copper(II) complexes that possess SOD-like activity, the 
arrangements of the ligand around the copper (II) should allow the reduction to 
copper(I). Moreover, there should be an accessible site for the O2•- and hydrogen 
bonding sites close to the metal centre. In fact, it has been demonstrated that the 
hydrogen bond may promote the SOD activity48,49. 
The complexes studied seem to fulfil these requirements. First, the N3O donor set 
provided by the pyridines and the tertiary amine can be considered a structural 
model of the His residues, while the phenol group as hydrogen bonds 
donor/acceptors. Furthermore, the ligands are flexible, hence they are able to 
accommodate the geometrical change from Cu2+ (square planar arrangement) to 
Cu+ (distorted tetrahedral arrangement), while the O2•- can easily access to the metal 
centre. 
The superoxide dismutation activity was evaluated through the indirect method with 
Cytochrome C, described by McCord and Fridovich50. This experiment provided the 





Figure 69: Scheme of Cytochrome C reduction to Ferricytochrome through superoxide radical anion, 
generated by xanthine/xantine oxidase system. 
In this specific method, superoxide radical anion is generated in a buffered solution 
(PBS, pH=7.8) by a xanthine/xanthine oxidase system, in the presence of 
cytochrome C (CytC). The xanthine is oxidized to urate by oxygen, producing the 
O2•- species, which reduces Cytochrome C to Ferricytochrome to yield molecular 
oxygen (Figure 69). A catalyst with SOD activity competes with the Cytochrome C in 
the scavenging of superoxide radical anion, thus inhibiting its reduction to 
Ferricytochrome. Since Ferricytochrome absorbs at 550 nm, the kinetics can be 
followed over time by UV-vis spectroscopy. What is measured with this assay is the 
IC50 value, the concentration of SOD mimic that causes 50 % of inhibition CytC 
reduction by superoxide radical and the catalytic constant, kcat, which can be 
calculated from the equation 20, note the reaction constant between CytC and O2• - 
(kCytC = 2.6 x105 M-1s-1) and IC50.  
𝑘𝑐𝑎𝑡 (𝑂2
•−)  =  
𝑘𝐶𝑦𝑡𝐶  [𝐶𝑦𝑡𝐶]
𝐼𝐶50
    (20) 
Since the kinetic of the superoxide radical anion is very fast, when the xanthine 
oxidase is added in the system, to evaluate the SOD activity, only the first, linear part 
of the curve was taken into account (< 0.3 min). The curve reaches the plateau when 
all the Cytochrome C is converted to Ferricytochrome. The conversion is total when 
in the sample there is no catalyst, while it is inhibited increasing the concentration of 





Figure 70: Trend of the absorbance over time at 550 nm, depending on the catalyst concentration. 
The black line corresponds to the total conversion of Cytochrome C to Ferricytochrome. The shades 
of grey from the dark one to the light one are relative to increasing amount of the catalyst in the 
sample, with these concentration: 0.16μM, 0.32 μM, 0.65 μM. 
The range between 0 and 0.2 minutes was considered and the trend lines were 
calculated, from which the slope and the intercept were obtained. Each experiment 
was repeated as a duplicate, hence the average of the slope was calculated. From 
these values, the % inhibition, depending on the copper (II) concentration is obtained 
(Figure 71).     
 
Figure 71: graph "concentration Cu (II) vs % inhibition" 
From the slope and the intercept in the plot “[Cu] vs % inhibition”, through the 
equation 21,  the IC50 values is calculated. 
𝐼𝐶50  =  
(50 − 𝑏) 
𝑎




The kcat is obtained from the following equation, where kCytc value is known in 
literature: 
𝑘𝑐𝑎𝑡 (𝑂2
•−)  =  
𝑘𝐶𝑦𝑡𝐶  [𝐶𝑦𝑡𝐶]
𝐼𝐶50
    (22) 
The values obtained from the different complexes are reported in Table 14. 
Table 14: IC50 values, catalytic constant for the superoxide radical anion dismutation e its logarithmic 
value, obtained with the indirect method. Condition adopted: [CytC] = 10μM, [catalase] = 15μg/mL, 
[xantine] = 40 μM , [xanthine oxidase] = 0.0053 U/mL, phosphate buffer 50 mM pH = 7.8 
Complexes IC50 (μM) kcat (s-1) log (kcat) 
Cu(HL1)(ClO4)2 1.41 1.83 x106 6.27 
Cu(HL5)(ClO4)2 1.04 2.62 x106 6.41 
Cu2(BPMP)(H2O)2(ClO4)3 1.21 2.18 x106 6.32 
 
The comparison with the literature values is complicated, because the IC50 values 
depends from the technique used for the analysis, while kcat is independent from the 
sample concentration and allows a better comparison. Moreover, various drawbacks 
have been highlighted on the use of NBT (nitro blue tetrazolium) instead of CytC as 
probe of O2•- scavenging. However, this assay have some problems because the 
NBT itself can mediate the formation of superoxide radicals. It also gives rise to a 
less stable signals, producing less reproducible kinetics and a overestimation of the 
kinetic constant47.  
Comparing the data of the complexes studied with the ones presented in literature 
(Table 15), it is possible to notice that in some case the characteristic values for the 
SOD activity are quite similar, like for [Cu(BPMPA)]+, while in other cases the data 
differs a lot, probably due to the different assay used in the analysis. Even if the 
complexes studied are less active than native Cu/Zn-SOD and other copper (II) 
complexes reported in literature, the dismutation of O2•- occurs with rate constant 
higher than two orders of magnitude respect to the self-dismutation constant (8 x 104 




Interesting is to compare the dinuclear complexes, previously obtained in this 
laboratory, with the same ligands HL1 and HL544. The dinuclear complexes with HL1 
and HL5 presents higher IC50 values with respect to the mononuclear complexes. 
Hence, the mononuclear complexes have a best SOD-like activity (Table 15), on the 
other hand, this suggests that the less stable dinuclear complexes do not fully 
convert to the corresponding mononuclear species in aqueous mixture.  
Among the complexes studied in this work, the one that presents the best SOD-like 
activity is Cu(HL5)(ClO4)2. Indeed, it presents the higher value for kcat and the lower 
for IC50, pointing out its highest inhibitory ability against the degradation of CytC to 
Ferricytochrome, therefore a greater tendency to eliminate the superoxide radical 
anion. 
Table 15: Summary of SOD activity express as IC50 and log (kcat) for the native Cu-ZnSOD and copper 
(II) mononuclear and dinuclear complexes; the values were obtained with a) NBT assay, b) CytC 
assay;c) dib=[2-(4,5-dihydro-1H-imidazol-2-yl)-1Hbenzimidazole-N,N,O],d)HBPMPA=N-propanoate-
N,N-bis-(2-pyridylmethyl)amine, e) TAAP = obtained by self-condensation of 5-amino-3-methyl-l- 








Native Cu-ZnSOD 0.04a 9.30 52,53 
Cu(SO)4 72.2b - 54 
Cu(HL1)(ClO4)2 1.41b 6.27 This work  
Cu2(L1)2(ClO4)2 1.99b 6.13 44 
Cu(HL5)(ClO4)2 1.04b 6.41 This work 
Cu2(L5)2(ClO4)2 1.28b 6.31 44 
Cu(dib)Cl2 c 0.09a - 55 
[Cu(BPMPA)]+d 1.04b 7.09 35 
Cu(TAAP)(NO3)2e 0.55a 7.26 49 
Cu2(BPMP)(H2O)2(ClO4)3 1.21b 6.32 This work 






2.4.3 Hydrogen peroxide dismutation: catalase-like activity 
Catalases efficiently disproportionate H2O2 to water and O2 , with kcat/KM 106–107M-
1s-1, without consuming additional electron-donor substrates57. Among synthetic 
analogues, complexes based on manganese show high activity. However, in the 
literature copper complexes with catalase activity are also presented.  
The mechanism proposed for the disproportionation of H2O2 for mononuclear copper 
complexes is proposed by Ramadan et al49. The reactions involve redox cycling of 
metal ion as follows: 
Mn+ + H2O2 → M(n-1) +HOO• + H+ (23) 
M(n-1) +HOO• + H+ + H2O2 → Mn+ + 2H2O + O2 (24) 
As regards the dinuclear copper complexes the mechanism, proposed by Gao et al58 
is shown in Figure 72.  
 




The first step allows to the two Cu (II) to bind to a molecule of hydrogen 
peroxide(stage 2). The hydrogen peroxide molecule promotes the reduction of metal 
centres from Cu (II) to Cu (I), with the release of an oxygen molecule (stage 3). A 
second molecule of hydrogen peroxide is bridged between the metal centres (stage 
4) and after the homolysis of the peroxo bond (stage 5), two protons are added 
(stage 6) and two molecules of water are realised, obtaining the starting complex 
(stage 1). The presence of two metal ions allows the coordination of H2O2 and 
facilitate the bi-electronic oxidation and reduction processes. 
The studied complexes catalase-like ability was evaluated by monitoring the 
pressure developed by the oxygen resulting from the dismutation of the hydrogen 
peroxide over a period of about 22 hours. For the analysis, a borate-based buffer 




Figure 73: O2 production over time, generated from the hydrogen peroxide dismutation. The trends 
obtained fort the preformed complexes with HL1 (blue), HL5 (red), HBPMP (green) are the result of 




Examining the graph "μmol O2 vs Time" (Figure 73), in which the μmol were obtained 
through the application of the law of "Perfect Gases" (equation 25), it is possible to 
note very different behaviour for the various catalysts. 
 
𝜇𝑚𝑜𝑙 (𝑂2)  =  
(𝛥𝑝 ∙  𝑉)
(𝑅 ∙ 𝑇)
 ∙ 1000000 (25) 
where Δp = pressure variation 
 V= gas volume = head volume= 0.0146 L  
 R = 0.0831 (atm·L)/(mol·K) 
 T = 298 K  
In particular, the mononuclear complex with the ligand HL1 presents an induction 
time before it starts its activity, probably due to the reorganization around the copper 
centre before it starts an efficient conversion of hydrogen peroxide. Also the 
dinuclear complexes with HBPMP exhibits a short induction time. Instead, the 
complex with HL5 immediately induces the dismutation of hydrogen peroxide.  
The maximum rate conversion (R0), the number of turnover (TON) and the frequency 
of turnover (TOF) are the characteristic parameters of catalysts classification and 
are reported in Table 16. 
Table 16: Average values, obtained from triplicate experiments, of R0, TON, TOF, %O2 and umol of 
O2 generated after about 22 hours. Condition: [catalyst]= 200 μM,[H2O2]=30 mM in BBS 50 mM 











Cu(HL1)(ClO4)2 300 0.34 0.14-8.49 1750 59 141.3 
Cu(HL5)(ClO4)2 - 0.52 0.21-13.07 1400 55 131.6 
Cu2(BPMP) 
(H2O)2 (ClO4)3 
70 0.67 0.28-16.71 600 62 147.7 
Cu2(L1)(ClO4)2 a 200 0.74 0.31-18.55 800 58 - 





The value of R0 corresponds to the maximum slope of the curve, below a conversion 
percentage of 30%, where an approximately linear trend is followed, and it is 
expressed in μmol / min. The value of TON is the ratio between the moles of oxygen 
developed and those of catalyst, while the TOF is the ratio between R0 and the moles 
of catalyst, and it is expressed in min-1. The best activity is showed by the dinuclear 
complex with HBPMP: in fact, it exhibits a relative high value for R0, and the highest 
value for TON and umol of O2. Comparing the  mononuclear compounds studied 
with the dinuclear ones, analysed in a previous work44, some differences are 
presented. As regard the ligand HL1 the values of TON are quite similar, while R0 
differs a lot. With regard to the ligand HL5, however, both the TON and R0 values 
are higher than the dinuclear complex. The important factor to take in account is that 
the catalase studies for the dinuclear complexes with HL1 and HL5 were carried out 
over a period of about 12 h44. While the mononuclear complexes reach the maximum 
O2 production over a double period (about 22h). This is in agreement with the 
hypothesis that the dinuclear complexes in solution act as the mononuclear ones, 
so that the amount of active species is twice than the mononuclear ones.  
To clarify the nature of the mechanism, and to exclude the presence of Fenton type 
reactions in the dismutation of the hydrogen peroxide effected by the complex, the 
catalase experiments were carried out in presence of KBr, a radical scavenger of 
HO•. The studied was led for the mononuclear complexes with HL1 and HL5 and 
pointed out that in the presence of KBr, the micromoles of oxygen production 
increases (Figure 74). In particular, the KBr addition, in the case of the mononuclear 
complex with HL1 removes the induction time and this allows to reach the plateau in 
O2 production in a shorter time (400 min). Concerning the Cu(HL5)(ClO4)2 complex, 
the presence of KBr increases the production of O2, which reaches its maximum in 
about 300 minutes. Therefore, the addition of KBr, as a radical scavenger makes the 





Figure 74:O2 production over time, generated from the hydrogen peroxide dismutation. A) trend 
obtained for preformed complexes with HL1 (blue) and in presence of 50mM KBr (light blue); B) trend 
obtained for the preformed complex with HL5 (red) an in presence of 50mM KBr (light red). 
Table 17: Comparison between the data obtained without and in presence of KBr. Conditions: 
[catalyst]= 200 μM,[H2O2]=30 mM in BBS 50 mM pH=7.8. 
Complexes [KBr] (mM) R0 (μmol/min) TON O2 (μmol) 
Cu(HL1)(ClO4)2 0 0.34 59 141.3 
Cu(HL5)(ClO4)2 0 0.52 55 131.6 
Cu(HL1)(ClO4)2 50 1.47 85 203.4 
Cu(HL5)(ClO4)2 50 1.26 84 201.6 
 
The catalytic process was also followed by UV-Vis spectroscopy, in order to obtain 
information about the molecular events that take place during the dismutation of 
hydrogen peroxide. The UV-Vis spectra were recorded at regular time intervals, 
according to the kinetic observed with the previous experiments. The spectra 
collected point out a variation in the shape of the absorption bands, with loss of some 
spectral characteristics. This indicates that the complex undergo degradation during 
the dismutation of the hydrogen peroxide, with major changes occurring after the 









































































O2 (umol) abs at 294 nm
 Figure 76: A) Cu(HL5)(ClO4)2 UV-vis spectra at t=0 (red) and after 7 h (light red). The colours 
variation represents an increment of 5 min from t=0 to t=15 min, of 15 min from t=15 to t= 45 min and 
45 min from t= 45 to t=360 min. Conditions: [Cu(HL5)(ClO4)2]= 200 uM, [H2O2]=10mM in BBS 50mM 
pH=7.8. B) O2 (red) and Abs (light red) trend at 294 nm over time. 
Figure 75:  A) Cu(HL1)(ClO4)2 UV-vis spectra at t=0 (blue) and after 8 h (light blue). The colours 
variation represents an increment of 45 min from t=0 to t=225 min, of 10 min from t=225 to t= 305 
min and 45 min from t= 305 to t=485 min. B) Conditions: [Cu(HL1)(ClO4)2]= 200 μM, [H2O2]=10mM 









Figure 77: : A) Cu2(BPMP)(H2O)2(ClO4)3 UV-vis spectra at t=0 (green) and after 6 h (light green). 
The colours variation represents an increment of 10 min. Condition: [Cu2(BPMP)(H2O)2(ClO4)3]= 200 
uM, [H2O2]=10mM in BBS 50mM pH=7.8. B) O2 (green) and Abs (light green) trend at 304 nm over 
time. 
For the complex with HL1 the mutation of the band occurs in a longer time, due to 
the induction time previously observed (Figure 75). The absorbance relative to the 
π→π* transition gradually decreases, and simultaneously the production of 
molecular oxygen increases. This behaviour suggests a reorganization in the 
coordination sphere of the complex, required to start the reaction. The characteristic 
band disappears after 4 hours. On the other hand, the spectra of the complexes, 
Cu(HL5)(ClO4)2 and Cu2(BPMP)(H2O)2(ClO4)3 undergo a faster modification (Figure 
76 and Figure 77). The band π→π* disappears after about 60 minutes, therefore the 
stability of these complexes is lower than that of the mononuclear one with HL1. As 
a matter of fact, the R0 values for these complexes are higher than the one obtained 
for Cu(HL1)(ClO4)2. After 7 hours the active species degrade and the O2 production 
increase. Interesting is the behaviour of the Cu2(BPMP)(H2O)2(ClO4)3, where the 
Abs at 304 nm increases till 100 min, then decrease and at the same time the 
production of O2 increases (Figure 77). The trend could be attributed to the formation 
of a different active specie that catalyse the dismutation of hydrogen peroxide.   
The evolution of mononuclear complexes during the catalase activity was also 








































Figure 78: A) trend for the ion [CuL1]+ (m/z 367.1) relative to the complex Cu(HL1)(ClO4)2, the data 
were collected from t=0 to t=24h, each 60 minutes; B) trend for the ion [CuL5]+ (m/z 397.1) of the 
complex Cu(HL5)(ClO4)2, the data were collected from t=0 to t=24h, each 30 minutes. Conditions: 
[complex]= 50μM, [H2O2]= 7.5mM in BBS 25 mM pH = 7.8. 
The graphs in Figure 78 confirm what is observed in the catalase experiments and 
in the UV-vis studies. The induction time, characteristic of the mononuclear complex 
with HL1 is related to a slow decomposition of the initial species, before completely 
disappearing after 24 hours. On the other hand, the complex with HL5 is converted 
almost completely after 60 minutes, disappearing at 24 hours.  
In the active species degradation, it is also important to take into account a 
mechanism, where the hydrogen peroxide could cause the oxidative degradation of 
the ligands, as discussed below. On the other hand, as highlighted by the 
experiments with KBr, radicalic species can contribute to ligand degradation in the 
observed time. 
2.4.4 Peroxidase-like activity 
After measuring the antioxidant activity of the complexes, the pro-oxidant capabilities 
should also be checked. In fact, the antioxidant studies were carried out in the 
absence of oxidizable substrates. Therefore, it becomes important to verify the 
oxidation of organic substrates, including different biological targets. The peroxidase 
activity involves the activation of H2O2 in order to convert it in strongly oxidizing 
peroxidic or radical species. The pro-oxidant activity of the obtained metal 




Fenton type radical reactions. The peroxidase activity was evaluated by UV-Vis 
spectroscopy, monitoring over time the absorbance variation of different substrates 
undergoing the oxidation. We used two different types of substrate: the morin and 
the o-phenylenediamine (OPD).  
The oxidative degradation of the morin takes place with a radical mechanism (Figure 
79). Observing the UV-Vis spectra, it is possible to notice a decrease in the 
absorbance of the characteristic band of morin, at 390 nm and the contemporaneous 
increment at 330 nm, relative to the products formation (Figure 81, A). 
 
Figure 79: Oxidative degradation of morin and the conditions used in the experiment. 
As well as the oxidation of OPD, colourless and non-fluorescent, takes place with a 
radical mechanism to produce 2,3 diaminophenazine (DAP), a fluorescent 
chromophore (Figure 80). In this case, the variation of the absorption due to the 
formation of the product is monitored. The spectrum shows an increase in the DAP 
band at 418 nm and a decrease in the one relating to the OPD at 220 nm (Figure 
81, B).  
 





Figure 81: Absorbance trend over time (18h) in the test with morin (A) and OPD (B), in the presence 
of the preformed complex Cu(HL1)(ClO4)2. The trend for the other complexes are reported in Figure 
82 and 83. 
 
Figure 82: Trend over time of the relative absorbance at maximum absorption of morin at 390 nm , 
with Cu(HL1)(ClO4)2 (blue), Cu(HL5)(ClO4)2 (red) and Cu2(BPMP)(H2O)2(ClO4)3 (green). 
The graphs “Abs vs time” highlight that the complex with the highest peroxidase-like 
activity is the dinuclear one (Figure 82, Figure 83). Indeed, it presents the highest 
pro-oxidant capability with both substrates. In the Figure 83, it is possible to notice 
that for all the three complexes analysed, the absorbance, relative to the formation 
of the product DAP decreases, starting from about 7 hours, likely due to the 
overoxidation of OPD oxidation product. 
In conclusion, all complexes studied present both antioxidant and oxidizing activity. 




CAT-like activity, but also the higher pro-oxidant capability. Due to the poor stability 
of the complexes under oxidising conditions, ascribed to the involvement of radicalic 
species, this behaviour is still difficult to rationalize in terms of mechanistic events. 
 
Figure 83: Trend over time at maximum absorption of DAP at 418 nm , with Cu(HL1)(ClO4)2 (blue), 



















2.5 Antiaggregation proprieties 
The neurodegenerative disorders are associated to a dysfunction in the metabolism 
of metal ions. In fact, the metal ions are involved in Alzheimer’s disease (AD), due 
to their ability to induce the aggregation of amyloidogenic peptide and to the 
production of Reactive Oxygen Species (ROS). The amyloid plaques are a hallmark 
in the brain of Alzheimer’s disease victims. These plaques consists mainly of an 
aggregated peptide dubbed amyloid-β (Aβ), which in healthy brains is present in 
soluble form. The formation of amyloid plaques is a peculiar phenomenon in AD 
patients, hence the processes that cause the transformation of the soluble Aβ into 
plaques are key events59. Another important characteristic of AD is the presence of 
oxidative damage on neuronal lipids and proteins. This is a clearly evidence of a link 
between  oxidative stress and the development of disease. The copper ions are 
accumulated in amyloid plaques, where they bind to Aβ. These complexes are able 
to catalyse the production of the ROS60.  
The amyloid peptides in buffer, at physiological condition are in a random coil 
organization, while in membrane mimicking media the structure is mainly in α-helical. 
The aggregation process involves the transformation in the cross β-sheet structure. 
In order to inhibit the aggregation promoted by the metal ions, the challenge is to 
design molecules that mimic the coordination site of Aβ peptides for metal ions, as 
in the case of metal chelators. Whereas the hydrophobic interactions can be inhibited 
by the β-sheet breaker, which have high affinity for the central hydrophobic 
sequence, KLVFF, of the peptide.  
In N-terminal moiety of Aβ is located the high affinity binding sites for Cu(II). At 
physiological condition, the coordination sphere for Cu(II) is characterized by four 
equatorial ligands: NH2 of Asp1, the C=O of the peptide bond between Asp1 and 






Figure 84: Aminoacid sequence for amyloid peptides 1-40 and 1-42 (top) and coordination site of 
amyloid peptides for Cu (II) ion (bottom). 
The Aβ40 peptides are used for the aggregation tests, because of their higher 
solubility and slower aggregation. Even if they are less toxic than Aβ42, these 
proprieties allow a deeper studied with different techniques. The aggregation 
experiments were carried out through the Tht fluorescence assay (Thioflavin T). Tht 
aggregates to the generated structures, inducing an increase in fluorescence. First, 
the amyloid peptides were dissolved in 1,1,1,3,3,3-Hexafluoro-2-propanol, a solvent 
that can promote the unfolding. After, the peptide solution 0.2 mM in PBS 10 mM 
(NaCl 100 mM, pH=7.4) was prepared. To the solution, Tht 0.2 mM, prepared in the 
same buffer was added and the solutions 0.2 mM of copper, ligands and preformed 
complexes were prepared in methanol (Experimental section, chapter 4.6). When 
the inhibition process relative to the aggregation of peptides occurs, the fluorescence  





Figure 85: Tht fluorescence in the sample solutions listed in the legend, where P = amyloid peptide. 
[ThT] = 10 μM; [P] = 10 μM; solutions of complexes, binders at concentration 10 μM.  
The test showed that the presence of Cu (II) ions creates a strong interference in the 
measurement, therefore it was not possible to include the relative data. As regards 
the behaviour of the free ligands, they inhibit the aggregation in this order 
HL1>HBPMP>HL5. Probably, the simple and more hydrophobic structure of the 
ligand HL1 could interact better with the peptides, preventing the aggregation. The 
respective preformed complexes show a different behaviour. The preformed 
dinuclear complex presents the best antiaggregating activity, followed by the 
mononuclear complex with HL1 and HL5. In the case of HBPMP, the preformed 
complex inhibits better the aggregation with respect to the free ligand.  Concerning 
the preformed mononuclear complexes, HL1 exhibits a lower fluorescence than HL5, 
hence a better activity. However, the ligand HL1 presents the best antiaggregating 
activity with respect to the preformed complex. For HL5 the behaviour is the 
opposite, in fact, the complex exhibits the best antiaggregating activity with respect 
to the ligand (Figure 85). 
However, other techniques, like the transmission electron microscopy (TEM) should 
be taken into account, in order to confirm these studies also at longer incubation 






























The purpose of this work is to synthesize and characterize, from both the solution 
and the solid state point of view, mononuclear and dinuclear copper(II) complexes, 
stabilized by an N3O-donor ligand set, in order to verify their combined superoxide 
dismutase and catalase-like activity in aqueous media, under physiological-like 
condition. The challenge is to evaluate the possible use of these complexes, within 
an innovative multivalent approach for AD treatment. In order to establish the 
multivalence of these complexes, different experiments were carried out (Table 18): 
1. The titration of the ligands with Cu(II) solution, monitored by  UV-vis 
spectroscopy, allowed to assess their potential as copper chelators, by  
determining the stoichiometry and binding constants of in situ-formed 
complexes.  
2. To better understand the solution equilibria of in situ-formed complexes, the 
pH-metrical titrations were performed and monitored by UV-vis spectroscopy.  
3. Potentiometric titrations of ligands and complexes were collected to obtain 
the protonation constants and the speciation curves, as pH function, of the 
different species. At physiological-like conditions (pH=7.8), as regard the 
ligand HL1 and HL5 the formation of mononuclear complex [CuHL]2+ is 
confirmed, while for HBPMP the dinuclear complex [Cu2L]3+ is formed.  
4. Redox potential and proprieties of the Cu(II)/Cu(I) couple for the preformed 
complexes, was evaluated through cyclic voltammetry. The cyclic 
voltammograms for Cu(HL1)(ClO4)2 and Cu(HL5)(ClO4)2 are characterized by 
a quasi-reversible trend and the redox potential for Cu2+/Cu+ is situated within 
the range suitable for the superoxide radical anion dismutation. On the other 
hand the dinuclear complexes with HBPMP presents an irreversible redox 
behaviour, but the SOD activity is not precluded. Likely due to a favourable 
geometry around the copper ions.  
5. SOD-like activity was evaluated through the indirect method of CytC, 
monitoring by UV-vis spectroscopy the kinetic of CytC reduction to 




were obtained. The best activity is shown by Cu(HL5)(ClO4)2, which is 
characterized by the lower value of IC50 (1.04 μM) and the highest one for kcat 
(2.62 x106 s-1). 
6. The CAT-like activity was verified by monitoring the pressure generated by 
the molecular oxygen, during the dismutation of hydrogen peroxide. In this 
case, the dinuclear complex with HBPMP presents the best activity among 
the complexes studied. To better understand the events that occur during the 
catalytic process, the catalase experiment was also monitored by UV-vis for 
all the three complexes, and by ESI-MS (+) for the mononuclear complexes.  
7. Peroxidase-like activity, evaluated by UV-Vis spectroscopy, monitoring over 
time the absorbance variation of the bands relative to the substrate (morin 
test) or the oxidation product (OP test). In a timeframe comparable to the one 
used for the catalase-like experiments, all the complexes studied, present a 
pro-oxidant activity, which is particularly high for the dinuclear complex. 
8. Aggregation test, in presence of 1-40 Aβ amyloids, monitoring the 
fluorescence of ThT over a period of about 25 hours. From this test emerged 
that, concerning the ligands, the best activity is presented by HL1, while for 
the preformed complex Cu2(BPMP)(H2O)2(ClO4)3 acts as the best 
antiaggregation agent. 
In summary, the results obtained highlight that the complexes studied act as 
antioxidant and antiaggregation agents. Concerning the antioxidant activity of the 
mononuclear compounds, the complex Cu(HL5)(ClO4)2 displays the highest 
reactivity, both as SOD and as CAT mimetic system, with higher reactivity and no 
induction time. Despite its unfavourable negative redox potential, due to the 
presence of the electron donor group, the higher reactivity is likely ascribed to a more 
favourable geometry as well as to an easier rearrangement of the pre-catalyst to the 
active species. On the other hand, the more negative redox also affects the 
peroxidase-like activity, indeed Cu(HL5)(ClO4)2 presents the lowest tendency to act 
as oxidant.  
As regards Cu2(BPMP)(H2O)2(ClO4)3, this complex exhibits the highest CAT-like 




period of time compared with the catalase activity, all the complexes exhibits also a 
pro-oxidant capability, resulting from parallel activation mechanisms including 
radicalic pathways.  
Concerning the antiaggregation proprieties, these are promising in all cases, being 
more evident for the ligand HL1 and the complex Cu2(BPMP)(H2O)2(ClO4)3. Test in 
vitro are thus advisable, so to establish how all these observations may impart an 
overall cytoprotective effects.  
Future experiments will focus on the improvement of ligands design, in order (i) to 
increase the solubility of the complexes in physiological-like condition, (ii) to tune the 
redox proprieties of copper sites and (iii) to improve the stability under oxidative 
conditions. These goals could be achieved, for example, through the introduction of 
solubilizing tails, further hydrogen bond donors to assist substrate binding and 
















Table 18: Summary of the results obtained for each ligands 
 HL1 HL5 HBPMP 
Ligand 
structure 







1 1 2 
Kbind [M
-1] 6.3·103 4.4·103 7.8·103 
SOD: IC50 
[μM] 
1.41 1.04 1.21 
CAT: R0 
[μmol/min] 

















4. Experimental section 
4.1 Materials 
All commercially available reagents and solvents, provided by Sigma-Aldrich, Carlo 
Erba, Fluka and Genscript were used without further purification. MilliQ-deionized 
water (Millipore), with a Jetpore virgin ion-exchange resin was used for the buffer 
preparation and for spectrometric measurements.  
4.2 Instrumentation 
• pH-meter: pH was measured by using a Metrohm 827 pH lab instrument. 
• 1H-NMR spectra were recoded with a Bruker 200 spectrometer operating at 200 
MHz. The chemical shifts were assigned using Si(CH3)4 as reference (δ 1H-NMR= 
0 ppm). For the peaks multiplicity, the following symbols were used: s: singlet, d: 
doublet, t: triplet, q: quartet, m: multiplet. 
• FT-IR spectra were recorded with a Nicolet 5700-Thermo Electron Corporation 
instrument. Throughout the vibrational bands assignment, the following symbols 
were used: w: weak signal, m: medium signal, s: strong signal, b: broad signal. 
• UV-vis spectra were recorded with a spectrometer Varian Cary 50, using quartz 
cuvette with 1 cm optical path.  
• Fluorescence spectra were recorded with a plate reader, using a Tecan Infinite 
instrument.  
• ESI-MS (+) spectra were collected with an Agilent LC/MSD Trap SL 
spectrometer, by using a capillary potential of 1500V. The solvents used were  
CH3CN and H2O. 
• Catalytic measurements: superoxide dismutase test (SOD) were carried out 
with Varian Cary 50 instrument, using quartz cuvette with 1 cm optical path; 
hydrogen peroxide dismutation test (CAT) were performed using a reactor, 
equipped with a pressure transducer and a septum for the injection. 
• Electrochemistry: cyclic voltammetry experiments were executed using a Cell 




glassy carbon electrode (3 mm diameter, geometric surface area = 7 mm2) as the 
working electrode, Pt wire as the auxiliary electrode and Ag/AgCl (3M NaCl) 
electrode as the reference electrode. 
• Protonation constants of ligands and complexes were calculated using the 
software Hyperquad 2008 (Peter Gans, “Protonic Software”). 
• Potentiometry: the potentiometric titrations were carried out with a Titrando 905 
by Metrohm system equipped with combined pH electrode (Biotrode by Metrohm), 
which is dedicated for the measurement of very small volumes. The ligands and 
the complexes were dissolved in DMSO (5% v/v/H2O(HCl/KCl) in order to obtain 
a concentration of 1 mM. Except for Cu2(BPMP)(H2O)2(ClO4)3, dissolved in H2O 
(HCl/KCl), because it is soluble in aqueous media. The titrant (NaOH 0.1M) was 
added with a micrometric syringe, at 298 K in the pH range of 2.5-11.5, in an 
argon atmosphere. 
• X-ray measurements: the measurements were carried out with an Oxford 
Diffraction Gemini E diffractometer, equipped with a 2 K × 2 K EOS CCD area 
detector and sealed-tube Enhance (Mo) and (Cu) X-ray sources. Mo-Ka (λ = 
0.71073 4 Å) radiation was used in all cases. Data collection, reduction and 
finalisation were carried out through the CrysAlisPro software. The structures was 
solved by direct methods and subsequently completed by Fourier recycling using 
the SHELXTL-2013 software package61 and refined by the full-matrix least-











4.3 Ligands synthesis 
Synthesis of the intermediate BPMA: bis-(2-pyridylmethyl) amine 
The BPMA synthesis was carried out following the procedure described in the 
literature, by Hamman et al39.  
 
3.02 g (28.2 mmol) of pyridine-2-carboxaldehyde in 10 mL of methanol, at 0°C were 
slowly added to 3.02 g (27.9 mmol) of 2-(aminomethyl)pyridine in 10 mL of methanol. 
The dark yellow solution obtained was stirred for 1 hour at room temperature. 
Afterwards, 0.391 g (10.3 mmol) of NaBH4 were added at 0°C. During the addition, 
it is possible to observe the formation of a yellow foam, and the solution turned to 
dark orange. When the addition was completed, the reaction mixture was stirred for 
12 h at room temperature. The day after, the solution changed its colour to dark 
yellow and was poured over ice.  HCl 2M was added until pH 4 was reached, at this 
point the solution turned to dark orange. The mixture was dried in vacuo and the oil 
obtained was dissolved in 14 mL of water. The brown solution was washed with 5 x 
10 mL aliquots of CH2Cl2, until the organic phase became colourless. To the aqueous 
layer was added saturated Na2CO3, to reach pH 10. The solution was extracted with 
CH2Cl2 (8 x 10 mL) and the organic phase was dried with Na2SO4. The mixture was 
filtered and the solvent was removed under vacuum to obtain a dark brown oil (19.6 
mmol, 70%). 
ESI-MS(+) (m/z): 200.1 [C12H14N3]+; (calc: 200.12) 
1H-NMR (200MHz, CD2Cl2): δ: 8.65 (d, J= 4.3 Hz, 2H), 7.76 (td, J=11.0,5.5 Hz 2H), 







Synthesis of HBBPMA (HL1): N-(2-hydroxylbenzyl)-N,N-bis(2-
pyridylmethyl)amine  
This ligand was synthetized following the procedure described by Connor et al40.   
 
0.710g (5.82 mmol) of slicylaldehyde were dissolved in 17 mL of MeOH. After that, 
a solution of 1.1490 g (5.77 mmol) in 13 mL of MeOH was added. The colour of the 
solution was dark yellow. Then, three drops of glacial acetic acid were added, 
followed by the dropwise addition of solution containing 0.195 g (9.10 mmol) of 
sodium cyanoborohydride in 2.6 mL of MeOH. After the addition, no change in the 
solution colour was observed. The resulting solution was refluxed for 1 hour and 
stirred at 60°C. After this operation, the reflux was removed and the solution was 
stirred overnight at room temperature. HCl 2M was added till pH 4.1 (verify by pH-
meter). This addition caused a change in the colour from orange to light red. The 
solution was dried in vacuo, dissolved in 12.5 mL of saturated Na2CO3 and then 
extracted with CHCl3 (3 x 30 mL). The organic phase was dehydrated with Na2SO4. 
The mixture was filtered and the liquid was evaporated to dryness to obtain a dark 
red oil. The oil was purified with a chromatographic column (silica, DCM : MeOH 8:2, 
with NH4Cl-saturated eluent, to optimize the elution of the amine product, which 
otherwise interact with silica, slowing down the run). After the purification, the 
product was dissolved in dichloromethane and extracted with water (4 x 10 mL), in 
order to remove the NH4Cl. The organic phase was dried with Na2SO4 and filtered. 
The solvent was removed under vacuum to yield a red oil.  




ESI-MS(+) (m/z): 306.2 [C19H20N3O]+; (calc: 306.16) 
FT-IT (, cm-1): 3239(b), 3050 (w), 3014 (w), 2922 (w), 2801 (w), 2701 (w), 2602 
(w), 2388 (b), 2289 (b), 1375 (w), 1657 (w), 1600 (s),1586 (s), 1486 (s), 1435 (s), 
1374 (s), 1369 (s), 1287 (s), 1242 (s), 1159 (m), 1123 (m), 1088 (m), 1038 (s), 1010 
(s), 974 (s), 903 (m), 867 (m), 825 (w), 761 (s), 633 (w), 597 (w).  
1H-NMR (200MHz, CDCl3): δ 8.62-8.52 (m, 2H), 7.63 (td, J= 7.7, 1.8 Hz, 2H), 7.34 
(d, J=7.8 Hz, 2H), 7.22-7.13 (m, 3H), 7.06 (dd, J=7.5, 1.5 Hz, 1H), 6.91 (dd, J= 8.0, 
0.9 Hz, 1H), 6.77 (td, J= 7.3, 1.1 Hz, 1H), 3.87 (s, 4H), 3.79 (s, 2H) ppm. 
Anal. Elem. Calc. for C19H19N3O (%): C, 74.73; H, 6.27; N, 13.76; found: C, 74.13; 
H, 6.50; N, 14.13. 
 
Synthesis of BPMAMMP (HL5): 2-{[Bis(pyridin-2-ylmethyl)amino]methyl}-6-
methoxyphenol  




For the reaction 0.886 g (4.5 mmol) of BPMA, 0.658 g (4.3 mmol) of o-vanillin, were 
used in 25 mL of MeOH, 0.197g (3.13 mmol) of NaBH3CN in 2.5 mL of MeOH. The 
product  was purified with a chromatographic column, using as eluent  DCM : MeOH 
8:2, saturated with NH4Cl. 




ESI-MS(+) (m/z): 336.2 [C20H22N3O2]+; (calc: 336.17)  
FT-IT (, cm-1): 3058 (b), 3006 (b), 2912 (b), 2834 (b), 2802 (w), 2615 (w), 2358 (m), 
2333 (m), 1585 (s), 1479 (s), 1433 (s), 1387 (s), 1373 (s), 1299 (s), 1249 (s), 1130 
(m), 1070 (s), 1001 (m), 975 (m), 900 (w), 839 (w), 762 (s), 627 (w), 464 (w). 
1H-NMR (200MHz, CDCl3): δ 8.65 – 8.52 (m, 2H), 7.61 (td, J =7.7, 1.8 Hz, 2H), 7.37 
(d, J = 7.8 Hz, 2H), 7.22 – 7.05 (m, 2H), 6.86-6.81 (m,1H), 6.76 – 6.66 (m, 2H), 3.90 
(s, 3H), 3.87 (s, 4H), 3.80 (s, 2H) ppm. 
Anal. Elem. Calc. for C19H21N3O2 (%): C, 71.62; H, 6.31; N, 12.53; found: C, 70.55; 
H, 6.45; N, 12.47. 
 
Synthesis of HBPMP: 2,6-bis[(bis(2-pyridylmethyl)amino)methyl]-4-
methylphenol 
The ligand HBPMP was synthesized according to the procedure described by Torelli 
et al42, with some modification.  
 
Under a dinitrogen atmosphere, a mixture of bis(2-pyridylmethyl)amine (0.975 g, 4.9 
mmol) and triethylamine (1.01 g, 10 mmol) in 2,6 mL of dry THF were added 
dropwise to a stirred solution of 2,6-bis(chloromethyl)-4-methylphenol (0.525 g, 2.5 
mmol) in 5 mL of dry THF at 0°C. The addition caused the formation of a dark yellow 
precipitate. When the addition was completed, the resulting mixture was stirred at 
room temperature. After 2.5 days, the mixture was filtered, and the filtrate was 
concentrated under reduced pressure. The residue was dissolved in 30 mL of 
methylene chloride, washed with brine, and dried over anhydrous Na2SO4. After the 
filtration, the solvent was removed under vacuum and a brown oil was obtained. The 




MeOH 8:2, as eluent. The solution was evaporated to dryness at reduced pressure 
to yield a yellow oil. 
Yield: 0.256 g (0.48 mmol); 20% 
ESI-MS(+) (m/z): 531.2 [C33H35N6O]+ (calc: 531.29) 
FT-IT (ν, cm-1): 2920 (w), 2814 (w), 1712 (w), 1677 (w),1586 (s), 1570 (s),1474 (s), 
1430 (s), 1374 (m),1362 (s), 1298 (m), 1232 (m), 1126 (m), 1049 (m), 1001 (m), 
978 (m), 942 (w), 907 (w), 871 (w), 788 (m), 756 (s), 605 (b). 
1H-NMR (200MHz, CDCl3): δ 8.68 (d, J = 4.9 Hz, 4H), 7.77-7.75 (m, 8H), 7.17-7.30 
(t, 4H, partially overlapped with the peak at 7.27 ppm due to the residue solvent 
CHCl3), 7.19 (s, 2H), 4.45-4.31 (m, 8H), 4.06 (m, 4H), 2.32 (s, 3H) ppm ; peaks of 
residue solvent: δ 2.18 (s) ppm of (CH3)2CO, 3.50 (s) ppm of MeOH,3.76 (s) and 
1.75 (s) pp of THF, 7.27 (s) ppm of CDCl3.  
Anal. Elem. Calc. for C19H21N3O2 (%): C, 74.69; H, 6.46; N, 15.84; found: C, 
72.84; H, 6.51; N, 14.80. 
4.4 Complexes synthesis  
Synthesis of Cu(HL1)(ClO4)2 and Cu(HL5)(ClO4)2 
 
The synthesis of the complexes was carried out mixing equimolar solution of the 
ligands and Cu(ClO4)2 in MeOH or CH3CN. Slow evaporation and liquid / vapor 
diffusion technique were used to obtain the crystals. For the synthesis of the 
mononuclear copper complex 0.0905 g (0.30 mmol) of the ligand and 0.107 g (0.29 
mmol) of copper perchlorate for Cu(HL1)(ClO4)2 , and  0.0908 g (0.27 mmol) and 
0.105 g (0.28 mmol) of copper perchlorate for Cu(HL5)(ClO4)2 were used. 




Cu(HL1)(ClO4)2 (MW=567.82 g/mol) 
ESI-MS(+) (m/z): 367.1 [C19H18CuN3O]+ (calc: 367.07); 403.0 [C19H19ClCuN3O]+ 
(calc:403.05). 
FT-IT (, cm-1): 2358 (s), 2334 (s), 2251 (w), 1458 (s), 1375 (m), 1292 (m), 1262 
(w), 1101 (s), 877 (m), 818 (w), 758 (s), 670 (s), 622 (s). 
Anal. Elem. Calc. for C19H21N3O2 (%): C, 37.79; H, 3.84, N, 6.96; found: C, 37.25; 
H, 3.78; N, 7.18. 
Cu(HL5)(ClO4)2 (MW=597,85 g/mol) 
ESI-MS(+) (m/z): 397.1 [C20H20CuN3O2]+ (calc: 397.08); 497.0 
[C20H21ClCuN3O6]+(calc: 497.04) 
FT-IT (ν, cm-1): 3382 (b), 2356 (s), 2339 (s), 2011 (b), 1616 (m), 1490 (m), 1448 
(m), 1373 (w), 1355 (w), 1288 (m), 1238 (w), 1101(b), 917 (w), 782 (w), 665 (m), 625 
(m).   
Anal. Elem. Calc. for C19H21N3O2 (%):C, 39.01; H, 3.76; N, 6.82; found: C, 39.06; 
H, 4.00; N, 6.86. 
Single-crystal X-ray diffraction (XRD) study 
Single-crystal XRD experiments were carried out by Dr. Nadia Marino at the 
Dipartimento di Scienze Chimiche of Padova. Crystals suitable for the diffraction 
analysis were carefully chosen under the microscope, mounted on a nylon loop with 
the aid of either Paratone oil or Loctite glue, positioned over a goniometer head and 
transferred in the diffractometer collection chamber. The samples were collected at 
room temperature (R.T.), except in one case. Concerning the monomeric Cu(II) 
complex with the HL1 ligand, the crystals grown from CH3CN/Et2O could be 
successfully analyzed at R.T. by using some tricks to slow down the lattice solvent 
loss. Crystals grown from MeOH/Et2O, instead, decomposed too quickly out of the 
mother solution, even at low temperature, and every attempt to collect data at either 




Concerning the monomeric Cu(II) complex with the HL5 ligand, the crystals grown 
from CH3CN/Et2O appeared very stable and could be analyzed easily at R.T. with 
no special precautions at all. In this case, also the crystals grown from MeOH/Et2O 
could be successfully analyzed, as by collecting them at about 150 K, crystal 
decomposition was delayed enough to get a significant amount of data. 
Synthesis of [Cu2(BPMP)(H2O)2](ClO4)3 
The dinuclear complex was synthetized according to the procedure described by 
Torelli et al42, with some modification. 
 
0.0578 g ( 0.11mmol) of HBPMP were dissolved in a solution of water: acetone 1:1. 
After the complete solubilization, the solution appeared yellow and 0.0822 g (0.22 
mmol) of Cu(ClO4)2 in 2,5 mL of water was added dropwise. The solution turned to 
brown instantaneously and was stirred at room temperature for three hours. The 
crystallization of the product was obtained through the slow evaporation technique 
and with the interface method. In this last case, 2mL of diethyl ether were added, 
and the solution was allowed to stand at 4°C for 12h. 0.0342 g (0.0345 mmol, 32%) 
of brown crystals ware recovered.  
ESI-MS(+) (m/z): 727.2 [C33H37ClCuN6O7]+ (calc: 727.12); 745.2 [C33H39ClCuN6O8]+ 
(calc: 745.18) 
FT-IT (, cm-1): 3535 (b), 3399 (b), 2927 (w), 2860 (w), 23362 (m), 2338 (w), 2023 




Anal. Elem. Calc. for C19H21N3O2 (%): C, 37.28; H, 4.27; N, 7.90; found: C, 
37.97; H, 4.11; N, 7.69. 
4.5 Measurement of the catalytic activity 
Cyclic voltammetry  
The cyclic voltammogram of the complexes were carried out with a three-electrode 
setup system: a working electrode (GCE, glassy carbon), a counter electrode (Pt) 
and a reference electrode Ag/AgCl (NaCl 3M). A phosphate buffer (PBS) 10 mM with 
NaCl 0.1 M, as a supporting electrolyte was prepared. For each mononuclear 
complex, 3 mL of solution CH3CN (5% v/v)/ PBS, with 0.50 mM of the catalyst, were 
prepared. Concerning the dinuclear complex, the concentration of the catalyst was 
0.25 mM, and the solution was made in PBS, because this complex is soluble in 
water. Prior to each experiment, the electrode was cleaned with alumina, washed 
with water and wiped with a paper tissue. Nitrogen was used to as a purging gas to 
remove dioxygen, upon bubbling for 15 min before each measurement. Before the 
acquisition of the sample solutions, the behaviour of the solutions with CH3CN (5% 
v/v)/ PBS, and only PBS were checked. The measurement was carried out between 
400 and -500 mV, with a scan rate equal to 50 mV/s. The voltammogram of the 
mononuclear complexes were also recorded at different scan rate: 100, 200, 400 
and 800 mV/s. 
Superoxide radical anion dismutation: SOD test 
The SOD-like activity was studied, using an indirect method with Cytochrome C 
(Cytc C), primarily described by McCord and Fridovich, with some modifications50. 
Using UV-vis spectroscopy, it was possible to evaluate the screening of the inhibition 
of Cytochrome C reduction to Ferricytochrome, due to the superoxide radical anion, 
oxidized to hydrogen peroxide. The radical anion was produced by 
xanthine/xanthine oxidase system, in situ. Since Ferricytochrome absorbs at 550 
nm, the trend of absorbance at this wavelength was monitored over time.  




o Phosphate buffer solution 50 mM pH = 7.8, in deionized water; 
o Xanthine solution, in deionized water; 
o Cytc C stock solution: 15.4 mg of Cyc C in 120 mL of phosphate buffer and 5 
mL of Xanthine; 
o Catalase (Cat) stock solution 15 μg/mL, in deionized water, in order to 
scavenge hydrogen peroxide produce by dismutation of superoxide radical;  
o Catalyst solution 100 μM in CH3CN, in the case of mononuclear complexes, 
in deionized water for the dinuclear complex. 
The sample solutions were prepared in a quartz cuvette, with 1 cm optical path, 
respecting the addition order, shown in Table 19. 
Table 19: Samples composition for the SOD activity determination. 
Addition order 1° measure 2° measure 3° measure 4°measure 
1. Stock sol. Cytc C 3 mL 3 mL 3 mL 3 mL 
2. Stock sol. Cat 10 μL 10 μL 10 μL 10 μL 
3. Phosphate buffer 30 μL 25 μL 20 μL 10 μL 
4. Catalyst 0 μL 5 μL 10 μL 20 μL 
5. Xanthine oxidase 20 μL 20 μL 20 μL 20 μL 
 
The last addition is the one relative to xanthine oxidase, since the production of 
superoxide radical anion was instantaneous, the acquisition must start immediately 
after the addition.  
From the linear plot of “% inhibition of Cytc C reduction vs effective catalyst 
concentration”, the IC50 values of the complexes was extrapolated. The catalyst 
kinetic constant kcat, relative to superoxide radical anion scavengeing was calculated 
from the equation: 
kcat (O2•-) = kCytcC  * [CytcC]/ IC50 




The measurement was duplicated and the experiment was carried out three times, 
for every complexes.   
Hydrogen peroxide dismutation 
The catalase activity was evaluated by monitoring the pressure developed by the 
oxygen, resulting from the dismutation of the hydrogen peroxide over a period of 
about 22 hours.  
The analysis was carried out by the use of a borate buffer (BBS). 12 mL of a solution 
with 30 mM of H2O2 (41 μL from [H2O2] = 8.8 M), and 200 μM of the catalyst (600 μL 
from the stock solution 4mM in CH3CN, in the case of the mononuclear complexes, 
and in deionized water in the case of the dinuclear one) were prepared in BBS 50 
mM pH = 7.8.  
The reactor, equipped with a septum, was closed and maintained at 25°C by a 
circulating thermostat. The measuring cell was connected to a transducer, in order 
to measure the variation of pressure in the head-space, due to the production of 
molecular oxygen, generated from hydrogen peroxide dismutation. The head-space 
volume of the reactor was equal to 14.6 mL. 
First, it was monitored the pressure of the solution without the catalyst. In fact the 
buffer solution with hydrogen peroxide did not generate molecular oxygen. After few 
minutes, required for signal stabilization, the catalyst was added through the septum.  
The law of perfect gas was used to evaluate the molecular oxygen micromole, 
developed in the head-space, at 25°C. The initial rates were calculated by linear 
regression of data at < 30% H2O2 conversion.  
Measurement of peroxidase like-activity 
The peroxidase activity can be evaluated by UV-Vis spectroscopy, monitoring over 
time the absorbance variation of the UV-Vis bands of different substrates, which 
were oxidized by H2O2, activated by the copper complexes studied. Two different 




The first substrate evaluated was the morin. The presence of hydrogen peroxide and 
a catalyst, with a peroxidase like-activity induced the oxidative degradation of the 
morine. This process was highlighted by the decrease in the absorbance over time, 
at the maximum absorption of morin, at 390 nm. The measurements were carried 
out in a phosphate buffer (PBS) 50mM (0.1 M NaCl, pH=7.8) at 25°C, using a quartz 
cuvette, with 1 cm optical path. The concentration used were: 3.2 μM of the catalyst, 
10 mM of H2O2 and 0.055 mM of morine. The kinetic were followed over a period of 
18 hours, acquiring the absorbance at intervals of 20 minutes.  
The second substrate was the o-phenylenediamine (OPD), that oxidizes to 2,3-
diaminephenazine (DAP), a colour and fluorescent compound. The kinetic was 
carried out following the increase in absorbance at 420 nm, due to the formation of 
DAP. For this analysis a phosphate buffer (PBS) 50mM (0.1 M NaCl, pH=7.8) at 
25°C, a quartz cuvette, with 1 cm optical path and the following concentration were 
used: 3.2 μM of the catalyst, 0.024 M of H2O2 and 0.32 mM of OPD. The kinetic were 
followed over a period of 18 hours, acquiring at intervals of 20 minutes. 
4.6 spectroscopic measurements 
Ligands and complexes scanning  
UV-vis scanning for ligands and complexes were carried out in quartz cuvette, with 
1 cm optical path. Concerning the ligands, the solution used were in MeOH (5% 
v/v)/H2O at concentration of 0.1 mM. For Cu(HL1)(ClO4)2 and Cu(HL5)(ClO4)2  the 
solution were in  MeOH (5% v/v)/H2O at 0.1mM and 1.5mM, in order to highlight, 
respectively, π→π and d→d bands. [Cu2(BPMP)(H2O)2](ClO4)3 was analysed in 
water, at 0.1mM and 1.5mM. 
Studying of the chelating ability trough titration by UV-vis spectroscopy 
Two solution of the ligands at 0.1 mM and 1.5 mM in MQ water were prepared, from 
the stock solution 4 mM in MeOH. These solutions were titrated with CuCl2 solution, 




A quartz cuvette, with 1 cm optical path was filled with 2.5 mL of the ligand solution, 
then aliquots of 2.5 μL of copper (II) solution were added (0.1 eq of  Cu2+, for each 
addition). After each addition, the absorbance variation, by UV-vis scans was 
followed from 200 nm to 800 nm. The graph “Abs at λmax vs Cu(II) equivalent” was 
created, in order to highlight the amount of Cu2+, that was bound to the ligand. The 










Where A0 is the ligand absorbance without the metal; A is the ligand absorbance for 
an addition of the metal; Amax is the absorbance recorded from the maximum 
concentration of the metal; K is the binding constant. The binding constant K is 
obtained from the slope in the plot  “1/(A-A0) vs 1/[Cu2+]”. 
Stechiometry detemination by Job’s Plot 
The method of continuous variations, or Job’s plot is a method that allows the 
stoichiometry determination of a binding event. Particularly, it highlights the 
formation of the complexes with 1:1 stoichiometry. The experiment is based on  the 
Uv-vis spectra acquisition of in situ generated complex, from 200 to 800 nm. In each 
scan, the molar ration of the metal and the ligand were changed, but the total mole 
number of the system remains constant. Concerning the study of the monuclear 
complexes, two solutions of 0.75 mM, one of the ligand and one of CuCl2 were 
prepared, in MQ water. For the dinuclear complex, a lower concentration was used 
(0.375mM), due to the precipitation of the ligand in aqueous media. In a quartz 
cuvette, with 1 cm optical path, different ratios of ligand an metal were added , 






Table 20: Samples composition for the determination of stechiometry by Job’s Plot, for HL1 and 
HL5. 
N° scans μmol Cu μmol HLX μmol tot V (μL) Cu 
V (μL) 
HLX 
V (μL) tot 
1 0 2.25 2.25 0 3000 3000 
2 0.225 2.025 2.25 300 2700 3000 
3 0.450 1.800 2.25 600 2400 3000 
4 0.675 1.575 2.25 900 2100 3000 
5 0.900 1.350 2.25 1200 1800 3000 
6 1.125 1.125 2.25 1500 1500 3000 
7 1.350 0.900 2.25 1800 1200 3000 
8 1.575 0.675 2.25 2100 900 3000 
9 1.800 0.450 2.25 2400 600 3000 
10 2.025 0.225 2.25 2700 300 3000 
11 2.25 0 2.25 3000 0 3000 
 
Table 21: Samples composition for the determination of stechiometry by Job’s Plot, for HBPMP. 
N° scans μmol Cu 
μmol 
HBPMP 
μmol tot V (μL) Cu 
V (μL) 
HBPMP 
V (μL) tot 
1 0 1.1250 1.125 0 3000 3000 
2 0.1125 1.0125 1.125 300 2700 3000 
3 0.225 0.900 1.125 600 2400 3000 
4 0.3375 0.7875 1.125 900 2100 3000 
5 0.450 0.675 1.125 1200 1800 3000 
6 0.5625 0.5625 1.125 1500 1500 3000 
7 0.675 0.450 1.125 1800 1200 3000 
8 0.7875 0.3375 1.125 2100 900 3000 
9 0.900 0.225 1.125 2400 600 3000 
10 1.0125 0.1125 1.125 2700 300 3000 





With these data, the graph “Amax vs Cu(II) equivalent” was obtained. The curve is 
characterized by a maximum at equal ratio of copper and ligand (maximum 
concentration of the complex in solution), when the stoichiometry is 1:1. On the other 
hand, in the case of the dinuclear complex, where the ratio between ligand and 
copper is 1:2, the curve presents a maximum at higher ratio of copper with respect 
to that of ligand.  
Aggregation test: ThT method 
Amyloid peptides Aβ1-40 were used for this analysis. 1 mg of the amyloid peptide 
was dissolved in 1 mL of 1,1,1,3,3,3-Hexafluoro-2-propanol and stirred for about 12 
hours at 4°C. Solvent was evaporated with a soft stream of N2 and re-dissolved in 
10mM phosphate buffer (NaCl 100mM, pH=7.4), to obtain a concentration of 77 μM 
(3 mL, MW = 4329.82 g/mol).  
A ThT fresh solution 0.04mM was prepared in 10 mM PBS buffer (NaCl 100mM, pH= 
7.4), from a mother solution 5mM in water. The concentration was checked by Uv-
vis spectroscopy, from the molar extinction coefficient (ε) of the band at 412 nm, 
equal to 36000 M-1cm-1. 
The solutions 0.2 mM of copper, ligands and preformed complexes were prepared 
in methanol.  
For the measurement a plate reader was used: in each cockpit (300 μL), the 
solutions were organized as follows: 
1. ThT 10 μM; 
2. ThT 10 μM, Aβ 10 μM; 
3. ThT 10 μM, Aβ 10 μM, HL1 10 μM; 
4. ThT 10 μM, Aβ 10 μM, HL5 10 μM; 
5. ThT 10 μM, Aβ 10 μM, HBPMP 10 μM; 
6. ThT 10 μM, Aβ 10 μM, Cu(HL1)(ClO4)2 10 μM; 
7. ThT 10 μM, Aβ 10 μM, Cu(HL5)(ClO4)2 10 μM; 




Every solution was brought up to volume with PBS buffer 10 mM (NaCl 100mM, pH 
= 7.4). 
The fluorescence of sample solutions was monitored at 37° C over a period of about 
30 hours, acquiring values every 20 minutes. The fluorescence variation of ThT was 











































5.1 1H-NMR, ESI-MS, FT-IR, UV-vis spectra 
 










ESI-MS (+) spectrum (CH3CN, m/z) of BPMA 
5.1.2 N-(2-hydroxylbenzyl)-N,N-bis(2-pyridylmethyl)amine (HL1) 
  














UV-vis spectrum of the ligand HL1 (MeOH 5% v/v/H2O, 0.1 mM, optical path= 1 cm) 
5.1.3 Complex Cu(HL1)(ClO4)2 
 







IR spectrum of the complex Cu(HL1)(ClO4)2  (KBr) 
 







5.1.4 2-{[Bis(pyridin-2-ylmethyl)amino]methyl}-6-methoxyphenol (HL5) 
 
1H-NMR spectrum (200 MHz, CDCl3) of the ligand HL5 
 





IR spectrum of the ligand HL5 (KBr) 
 







5.1.5 Complex Cu(HL5)(ClO4)2 
 
 
ESI-MS (+) spectrum of the complex Cu(HL5)(ClO4)2 (4x10-5M, CH3CN, m/z) 
 
 



























5.1.6 2,6-bis[(bis(2-pyridylmethyl)amino)methyl]-4-methylphenol (HBPMP) 
 
 

















UV-vis spectrum of the ligand HBPMP (MeOH 5% v/v/H2O, 0.1 mM, optical path= 1 cm) 
 
 
5.1.7 Complex Cu2(BPMP)(H2O)2(ClO4)3 
 






IR spectrum of the complex Cu2(BPMP)(H2O)2(ClO4)3  (KBr) 
 








5.2 UV-vis titrations 
 
 
Titration of the ligand HL1 (0.1mM, Cu (II) 0.0-0.2mM H2O MQ); the light line is the one of the ligand, each 




Titration of the ligand HL5 (0.1mM, Cu (II) 0.0-0.2mM H2O MQ); the light line is the one of the ligand, each 





Titration of the ligand HBPMP (0.1mM, Cu (II) 0.0-0.2mM H2O MQ); the light line is the one of the ligand, each 
change in colour, till black represents the addition of 0.1 equivalent of copper. 
 
5.3 Peroxidase test 
Morine 
 
Absorbance variation of the morine, with the complex Cu(HL1)(ClO4)2. The black line is at t=0, while the light line 
is at t=18h. The concentration used were: PBS 50mM (0.1 M NaCl, pH=7.8),3.2 μM of Cu(HL1)(ClO4)2, 10 mM 





Absorbance variation of the morine, with the complex Cu(HL5)(ClO4)2. The black line is at t=0, while the light  
line is at t=18h. The concentration used were: PBS 50mM (0.1 M NaCl, pH=7.8),3.2 μM of Cu(HL5)(ClO4)2, 10 
mM of H2O2 and 0.055 mM of morine. 
 
Absorbance variation of the morine, with the complex Cu2(BPMP)(H2O)2(ClO4)3. The black line is at t=0, while 
the light line is at t=18h. The concentration used were: PBS 50mM (0.1 M NaCl, pH=7.8),3.2 μM of 







Increase in the absorbance at 420 nm of DAP in the presence of the complex Cu(HL1)(ClO4)2. The black line is 
at t=0, while the light  line is at t=18h. The concentration used were: PBS 50mM (0.1 M NaCl, pH=7.8),3.2 μM of 
Cu(HL1)(ClO4)2, 0.024 M of H2O2 and 0.32 mM of OPD. 
 
Increase in the absorbance at 420 nm of DAP in the presence of the complex Cu(HL5)(ClO4)2. The black line is 
at t=0, while the light green line is at t=18h. The concentration used were: PBS 50mM (0.1 M NaCl, pH=7.8),3.2 






Increase in the absorbance at 420 nm of DAP in the presence of the complex Cu2(BPMP)(H2O)2(ClO4)3. The 
black line is at t=0, while the light line is at t=18h. The concentration used were: PBS 50mM (0.1 M NaCl, 
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